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Lantibiotics are a subclass of a group of bacterially produced antimicrobial 
peptides called bacteriocins. They are characterized by post-translation modifications 
resulting in the presence of unusual amino acid residues such as dehydroalanine (Dha), 
dehydrobutyrine (Dhb) and lanthionine/methyllanthionine. Interest in using bacteriocins 
as alternative therapeutics in multiple settings has grown in recent years. Nisin in 
particular has been the subject of many studies due to it being well characterised, 
approved by the FDA, widely used as a food preservative (EU number E234) and having 
GRAS (generally regarded as safe) status. Nisin has bioengineered to generate multiple 
variants with advantageous properties, including enhanced antimicrobial activity. Nisin 
is also capable of inducing its own production (auto-induction) through the LisRK sensor 
kinase system. In Chapter 2 we examine the self-induction properties of a previously 
created nisin variant “nisin-AAA” by substituting positions K12 and H31 independently, 
revealing that ten variants retained the ability to induce the PnisA promotor (K12K/H31H, 
K12V, K12Q, K12W, K12T, K12A, K12C, H31N, H31K and H31R). Amino acid 
substitutions at positions K12 and H31 were also made simultaneously generating the 
variant K12V-AAA-H31V, a variant previously shown to be trypsin and chymotrypsin 
resistant, but which lost its capacity for self-induction. Our results confirm that amino 
acid substitutions R, N and K at H31 are the only substitutions capable of maintaining 
auto-induction. Given that all three are cut sites for trypsin or chymotrypsin we conclude 
that any substitution at position H31 of the nisin-AAA variant will lead to either loss of 
auto-induction or a peptide which is sensitive to digestion by chymotrypsin. 
The number of clinically significant bacteria becoming antibiotic resistant is 
increasing, along with concerns of pandrug-resistance (resistance to all current drugs), 
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emphasizing the need to introduce new therapeutics into the clinic. In Chapter 3, 
following an initial screening involving nisin, lacticin 3147 and several other 
bacteriocins, it was observed that bacteriocins could enhance the antimicrobial activity of 
classical antibiotics against selected clinically significant bacteria. Levels of antibiotics 
often associated with adverse effects and antibiotic resistance could be reduced in the 
presence of either lacticin 317 of nisin Z. Enhanced antimicrobial activity was seen 
between lacticin 3147 and penicillin G as well as vancomycin. In addition, methicillin 
(which is no longer used very much in clinical settings) showed partial synergistic activity 
in combination with nisin Z, suggesting the possibility of reviving old therapeutics with 
the aid of new antimicrobials. 
Given that the anti-cancer effects of bacteriocins have been largely unexplored, in 
Chapter 4 we investigate the potential use of nisn Z as an alternative treatment for 
colorectal and oesophageal cancers, which have with high incidence and poor prognosis. 
It was observed by morphological examination that nisin Z elicited apoptotic cell death 
in 4 colorectal cancer cell lines and potentially autophagy mediated cell death in 2 
oesophageal cancer cell lines. Confocal microscopy analysis along with flow cytometry 
profiles further supported autophagic cell death in oesophageal cell lines, whereas 
apoptotic cell death was supported in colorectal cell lines by flow cytometry. Upon further 
analysis it was observed that one colorectal cancer cell line, HCT116, initiated apoptotic 
cell death through the intrinsic pathway, as inferred by the upregulation of the protein 
caspase-9.  
As a consequence of the studies presented in this thesis, it is possible that 
strategies will emerge to facilitate the use of bacteriocins such as nisin Z and lacticin 3147 
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 Dramatic increases in the incidence of clinically significant antibiotic resistant 
bacteria and the occurrence of gastrointestinal cancers demands that novel solutions 
should be explored. One avenue that has gained growing interest is the use of certain 
bacterially produced antimicrobial peptides called bacteriocins, such as nisin and lacticin 
3147. Nisin and lacticin 3147 are both lantibiotics, a class of bacteriocins that are post-
translational modified and contain unusual lanthionine/methyllanthionine residues, 
among others. Given that few cases of naturally occurring lantibiotic resistance have been 
recorded, taken together with their antimicrobial activity at low concentrations, indicates 
their possible use as an alternative therapeutic to conventional antibiotics should be 
further examined. In addition, more recent studies have demonstrated anti-cancer effects 
with certain bacteriocins selectively binding to cancer cells, suggesting they may have a 
place in future oncological therapeutic strategies. Nisin has demonstrated considerable 
anti-cancer activity in vitro and in vivo, suggesting a possible use in human therapy. Nisin 
has also been granted GRAS (generally regarded as safe) status which, together with its 
status as one of the most characterised and well-studied lantibiotics to date, makes it a 
promising candidate for such therapies. Further bioengineering of the nisin peptide could 
also provide additional information to further enhance its activity or characterise structure 




Bacteriocins are antimicrobial peptides produced by both Gram-positive and 
Gram-negative bacteria. They can have either narrow (select bacterial types such as 
Gram-negative or Gram-positive) or broad (wider range of bacteria) spectrum 
antimicrobial activity. Many bacteriocins, such as the lantibiotics nisin and lacticin 3147, 
are produced by the food-grade lactic acid bacteria (LAB), Lactococcus lactis (L. 
lactis)1,2. Lantibiotics are ribosomally synthesised antimicrobial peptides that are subject 
to post-translational modifications resulting in the formation of unusual amino acids 
including lanthionine and -methyllanthionine bridges. These unusual amino acids are 
created enzymatically when a covalent bridge is formed between a cysteine (C) residue 
and a dehydrated serine (S) (dehydroalanine, Dha), or threonine (T) (dehydrobutyrine, 
Dhb)2. Nisin and lacticin 3147 are two of the most extensively characterised lantibiotics 
to date. Both exhibit a broad-spectrum of antimicrobial activity at nanomolar 
concentrations by means of cell wall biosynthesis inhibition and pore formation3–6. 
Bacteriocins have a number of advantages which give them a wide-ranging potential to 
be used as future biological therapeutics such as their amenability to bioengineering, 
having an immunomodulatory role, synergistic activity with other antimicrobials, 
selective toxicity towards cancer cells, antimicrobial activity against numerous antibiotic 
resistant bacteria, low occurrence of resistance, low toxicity in humans, and high stability, 
solubility and activity7–9. However, bacteriocins are also known to have a relatively short 
half-life within the body due to certain digestive enzymes (such as trypsin and 
chymotrypsin)10,11. 
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1.3 Lacticin 3147 
Lacticin 3147 is a two peptide lantibiotic comprised of Ltn which binds to the 
peptidoglycan precursor lipid II on the outer leaflet of the cytoplasmic membrane, and 
Ltn, which binds the Ltnα-lipid II complex and subsequently inhibits peptidoglycan 
synthesis and induces the formation of depolarising pores in the membrane of target 
cells3. It has displayed antimicrobial activity against numerous clinically significant 
pathogens, such as vancomycin-resistance enterococci (VRE), Cutibacterium acnes (C. 
acnes) (formerly known as Propionibacterium acnes), Staphylococcus aureus (S. aureus), 
penicillin-resistant Streptococcus mutans and Mycobacterium tuberculosis, along with 
synergistic activity with other antimicrobials (such as polymyxin B) against both Gram-
positive and Gram-negative strains (methicillin resistant Staphylococcus aureus (MRSA) 
and Escherichia coli respectively)s12–16.  
1.4 Nisin 
This 34 amino acid peptide consists of 5 lanthionine rings, is cationic with 5 
positively charged residues (Lysine (K) 12, K22, Histidine (H) 27, H31 and K34) and no 
negatively charged residues17–19. Like lacticin, nisin also interacts with lipid II resulting 
in cell wall biosynthesis inhibition and pore formation. Nisin A is an FDA and WHO 
approved GRAS (generally regarded as safe) peptide that has been used within the food 
industry as a preservative since 19537. In addition, many studies have demonstrated the 
antimicrobial activity of nisin against clinically and veterinary significant bacteria such 
as MRSA, Enterococcus faecalis and Streptococcus suis, as well as displaying synergy 
with antimicrobials such as ramoplanin, chloramphenicol and -lactams9. Since its 
discovery in 1928 nisin has been used in the food-industry as an alternative 
biopreservative, however in more recent years the potential applications of nisin within 
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the biomedical industry has expanded enormously8,20–23. Its role as an alternative 
therapeutic for various bacterial infections and cancers are just some of the possible 
avenues being investigated. 
1.4.1 Nisin variants 
To date eight natural nisin variants have been identified. Nisin A, Z, F and Q are 
produced by lactococci, variants U and U2 by Streptococcus uberis, nisin H by 
Streptococcus hyointestinalis, whereas nisin P is produced by both Streptococcus 
gallolyticus sbsp. pasteurianus and Streptococcus suis24. Nisin Z and A are closest in 
structure with only a single amino acid residue difference at position 27 (N and H, 
respectively)25. Nisin Z demonstrates a higher rate of diffusion and solubility, under 
neutral pH conditions, and has been isolated from several L. lactis strains26,27. 
One of the major advantages of lantibiotics over many traditional antibiotics is 
their gene-encoded nature. This makes them amenable to bioengineering, thus allowing 
for variants with additional advantageous properties to be developed. In addition to 
developing many variants with enhanced antimicrobial activity, stability and 
pharmacokinetic properties, bioengineering techniques have aided in the identification of 
peptide structure and function. Mersacidin and nukacin are both examples of bacteriocins 
that, after having undergone site-saturated mutagenesis, resulted in derivatives with 
enhanced bioactivity against clinically significant bacteria, such as MRSA, VRE and 
Streptococcus pneumonia28,29.  
Many nisin variants have been generated that demonstrate enhanced antimicrobial 
activity. In particular variants with targeted changes to the flexible hinge region at 
positions N20-M21-K22 exhibit enhanced activity against a host of clinically significant 
bacteria. Initially, two nisin Z mutants were generated, N20K and M21K, displaying 
enhanced activity against the Gram-negative bacteria Shigella, Pseudomonas and 
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Salmonella spp. and had a higher solubility when compared to wild type nisin Z30. This 
led to further studies involving the mutagenesis of the hinge region. Notably M21V 
displayed enhanced activity against a multitude of clinically significant bacteria, namely 
heterogenous vancomycin intermediate Staphylococcus aureus (hVISA), VRE, MRSA, 
Clostridium difficile (C. dificile), Streptococcus agalactiae (S. agalactiae) and Listeria 
monocytogenes31,32. Multiple variants with amino acid substitutions at position 29 have 
been shown to exhibit enhanced bioactivity against a range of drug resistant clinical, 
veterinary and food pathogens. Of those that were generated, two produced activity 
against both Gram-positive and Gram-negative pathogens, S29G and S29A33. Another 
study demonstrated that the bioactivity of nisin can be altered by changing the length of 
the hinge region34. Further studies involving the hinge region lead to the rational design 
of multiple variants (N20A-M21A-K22A (nisin-AAA) and N21S-M21A-K22A) 
exhibiting enhanced bioactivity against L. lactis HP, S. agalactiae ATCC 13813, 
Mycobacterium smegmatis MC2155 and S. aureus RF12235. This nisin-AAA variant was 
the subject of further bioengineering which resulted in the generation of a trypsin and 
chymotrypsin resistant variants10. Nisin is naturally inactivated by pancreatic and other 
proteolytic digestive enzymes such as trypsin and chymotrypsin upon ingestion, thus 
making it vulnerable to proteolytic breakdown in the gastrointestinal tract10,11. Trypsin 
and chymotrypsin cleavage sites in nisin A are located at positions 12, 20, 21, 22 and 31. 
By changing the amino acid residues at positions 12 and H31 of the nisin-AAA variant, 
trypsin and chymotrypsin cleavage sites were removed, allowing for potential survival 
upon entering the gastrointestinal tract10.  
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1.5 Bacteriocin-antimicrobial synergistic and additive effects 
With the incidence of antibiotic resistance on the rise, there is an urgent need for 
alternative therapies. The discovery of synergistic activity between bacteriocins and other 
antimicrobials may play a role in advancing the treatment of clinically significant 
pathogens13,36–40. With little evidence of resistance to lantibiotics, the combination of 
these antimicrobial peptides with classical antibiotics may help to reduce/overcome the 
emergence of resistance to the latter. With antimicrobials having varying levels of activity 
against different bacteria, combinations may allow for a broader range of pathogens to be 
targeted, including infections with unknown aetiology9. Furthermore, combining 
bacteriocins with other antimicrobial agents would allow for a decrease in effective dose 
and therefore could reduce adverse side-effects associated with certain antimicrobials9,41. 
Antibiotics, although frequently critical for patient recovery, can result in serious adverse 
side-effects. Polymyxin’s are strongly associated with neurotoxicity, nephrotoxicity and 
renal toxicity (affecting 6 to54% of all patients), and vancomycin, an antibiotic widely 
used for the treatment of MRSA, is commonly associated with nephrotoxicity42,43. Using 
antibiotics, known to have toxic effects on the body, in combination with bacteriocins 
may help to reduce the level of toxicity. 
1.5.1 Lacticin 3147 
To date, lacticin 3147 has not been reported to exhibit any antimicrobial activity 
against Gram-negative bacteria. However, in combination with Gram-negative targeting 
antibiotics polymyxin B and polymyxin E (colistin), synergistic antimicrobial activity 
against the Cronobacter sakazakii DPC6440 and E. coli was clearly demonstrated13. The 
same study also showed synergy against Gram-positive S. aureus 5247, and B. cereus 
8079 when lacticin 3147 was used in combination with polymyxin B13 
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1.5.2 Nisin 
Multiple studies have shown the benefits of combining nisin with antimicrobial 
agents. For example, nisin has demonstrated synergy with many conventional antibiotics 
against clinically significant strains, such ramoplanin (also targets lipid II) against MRSA 
and VRE, penicillin and chloramphenicol against E. faecalis, polymyxcins against 
Listeria innocua HPB13, Acinetobacter spp. and E. coli, and ciprofloxacin against MRSA 
and Methicillin sensitive Staphylococcus aureus (MSSA) strains36,37,44–47. Nisin has also 
demonstrated synergy with antibiotics such as vancomycin against MRSA strains, 
however the effect is not as dramatic, possibly due to their similar mode of action of 
binding to lipid II47. In the case of nisin-vancomycin, the binding of one antimicrobial to 
lipid II decreases the accessibility of lipid II to the second antimicrobial, thus combining 
antimicrobials that interact with different pathways are thought to elicit better synergistic 
activity45,48. In addition, nisin has also demonstrated antagonistic activity in combination 
with some antibiotics, for example nisin-chloramphenicol combinations against multiple 
MRSA strains44.  
Like lacticin 3147, the activity of nisin against Gram-negatives is poor but can be 
enhanced when used in combination with other antimicrobials such as polymyxin B and 
E, which have also proven to act synergistically with nisin against C. sakazakii, Listeria, 
E. coli and Pseudomonas aeruginosa13,33,49. Synergistic activity against S. aureus biofilm 
populations has also been demonstrated in multiple studies involving nisin and 
antimicrobial agents such as ciprofloxacin, daptomycin and lysostaphin50,51. Variants of 
nisin, such as M21V and I4V, have also proved to be effective in combination with 
antibiotics such as penicillin and chloramphenicol against planktonic and biofilm 
populations of S. aureus SA113 and Staphylococcus pseudintermedius DSM2128452. 
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 Antimicrobial agents other than antibiotics have also proven to work 
synergistically with nisin against an array of bacteria, including biofilm populations. Both 
sodium fluoride and polylysine work synergistically with nisin against biofilm and 
planktonic forms of S. mutans, as well as lactoferrin (secreted in the respiratory tract) 
working synergistically with nisin against L. monocytogenes and E. coli 0157:H78,38,53,54. 
In addition, nisin has displayed synergistic activity when used in combination with 
ethylenediaminetetraacetate (EDTA) against L. monocytogenes  and enterohaemorrhagic 
E. coli strains55. 
1.6 Nisin Induction 
1.6.1 Nisin biosynthesis   
The successful production of the mature nisin peptide is reliant on the inter-
communication of several proteins and genes, and the mature peptide plays a role in its 
own induction through the specific activation of these genes2,56–58. Biosynthesis of nisin 
is encoded by a cluster of eleven genes (A, B, T, C, I, P, R, K, F, E and G). The first gene, 
nisA, encodes for the nisin precursor with the remaining genes coding for proteins 
responsible for peptide modification, translocation and processing (nisB, nisC, nisP and 
nisT) the bacteria’s immunity against nisin itself (nisI, nisF, nisE and nisG) and regulating 
expression (nisR and nisK)59.  
The transmembrane histidine protein kinase NisK detects and binds to 
extracellular nisin before autophosphorylation. The subsequent phosphate group is 
transferred to, and activates, the intracellular response regulator NisR and triggers the 
activation of two promoters (PnisA and PnisF) on the nisin operon (Figure 1.1)2,56–58,60. This 
signalling by extracellular nisin to induce its own intracellular transcription is known as 
auto-induction.  
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To form the mature peptide, a precursor form of nisin with an N-terminal leader 
is first translated before being post-translationally modified. At this stage, selected serine 
(S) and threonine (T) amino acids are dehydrated by NisB and lanthionine bridges are 
formed by NisC. The peptide is subsequently exported out of the cell by NisT and cleaved 
of its N-terminal leader by NisP. The resulting peptide is fully mature and can now 
interact with NisK resulting in an auto-induction loop (Figure 1.1)2,56–58. 
Studies manipulating this process have shown that deletions in the structural nisA 
gene results in the termination of transcription, but this can be restored by the introduction 
of extracellular nisin peptide (and nisin variants) at sub-inhibitory levels. However when 
the nisK gene is disrupted the addition of extracellular nisin can no longer initiate the 
auto-induction loop2. One study showed that nisin can promote its own induction from 
within the cell itself58. The study concluded that the partial interaction of nisin with the 
signal recognition domain of nisK, within the water-soluble side of the membrane, was 
sufficient to induce a nisin auto-induction loop58.  
1.6.2 Nisin-controlled gene expression system 
The advantages of using this nisin auto-induction mechanism, termed the Nisin-
Controlled gene Expression (NICE) system, has been recognised and exploited for many 
years59,61. In recent decades, the NICE system has been used in the expression of 
numerous genes from diverse bacterial backgrounds and various applications, such as 
analysis of metabolic and enzyme function, and the production of greater quantities of 
protein for food, medical or technical applications52,59. Initially the nisKR genes, involved 
in signal transduction, were isolated and transferred into the pepN gene on the 
chromosome of L. lactis subsp. cremoris MG1363, a naturally plasmid and nisin free 
strain. This became known as NZ9000 and is the most  commonly used host57,59,62. A 
gene of interest can be placed behind the inducible promoter PnisA on a plasmid or the 
 21 
chromosome and, so long as NisRK are present, will be expressed when induced by the 
addition of sub-inhibitory amounts of nisin (0.1-5ng/ml)59.  
1.7 Antibiotic Resistance 
1.7.1 Global Significance 
Antibiotic resistance has become a global problem, so much so that governing 
bodies have been compelled to act. In 2015 the WHO (World Health Organisation) issued 
a “global action plan on antimicrobial resistance”63. After the United Nations general 
assembly in 2016 all members were required to implement their own national action plan 
for combating antibiotic-resistant bacteria by 2017. In 2015 the United States Federal 
Government put in place the “national action plan for combating antibiotic-resistant 
bacteria” and in 2017 the EU Commission began implementing the “EU one health action 
plan against antimicrobial resistance (AMR)”64.  
Both reports highlight the importance of slowing the emergence of resistance 
bacteria, preventing the spread of resistant infections, accelerating basic and applied 
research, innovation and the development of new antibiotics, other therapies and 
vaccines63,65. In 2015 the WHO launched the Global Antimicrobial Resistance 
Surveillance System (GLASS) in an effort to support AMR research and the global action 
plan on antimicrobial resistance, and provide more information for the implementation of 
national, regional and global actions66. By 2017, 42 countries enrolled in GLASS, 40 of 
which provided information on their AMR surveillance systems and 22 of which provided 
actual AMR data67. 
1.7.2 Causation  
Antibiotic resistance has become a global problem due to a multitude of factors, 
including: overuse, inappropriate prescribing, extensive agricultural use and the 
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availability of few new antibiotics68. It can occur through bacterial evolution, by 
spontaneous mutation or horizontal gene transfer (HGT). The overuse of antibiotics fuels 
the evolution of resistance, and allows for the accumulation of resistant bacteria and the 
passing of resistant genes through HGT, in some cases to very different bacteria68.  
1.8 Clinically significant antibiotic resistant bacteria 
Antibiotic resistance remains a problem for numerous bacterial species with some 
giving a greater cause for global concern than others. The GLASS report of 2016-2017, 
closely monitored eight human bacterial pathogens, considered to be the greatest threat 
globally, from multiple countries worldwide67. The U.S. Centre for Disease Prevention 
and Control (CDC) and the European Centre for Disease Prevention and Control (ECDC) 
have released similar lists of pathogenic bacterial strains under observation (Tables 1, 
2)69,70. 
1.8.1 Methicillin-resistant Staphylococcus aureus (MRSA) 
MRSA is one of the top globally significant antibiotic resistant pathogens, it is 
monitored by both the CDC and the ECDC. Staphylococcus aureus is a Gram-positive 
coccus and is ubiquitous in nature with approximately 20-30% of individuals displaying 
nasal passage colonisation persistently and 60% intermediately71–73. It causes a multitude 
of skin infections ranging from superficial pimples, boils and impetigo, to deeper skin 
infections such as abscesses and cellulitis. MRSA is also frequently associated with 
wound infections, with surgical sites and intravenous lines identified as contributing risk 
factors74–76. In 2010 a study involving 33 medical centres in 13 European countries and 
Israel demonstrated that 71.1% of all skin and soft tissue infection (SSTI) isolates were 
S. aureus, 22.5% of isolates being methicillin resistant, and 9.3% were enterococci, 5.1% 
being VRE77.  
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In the 1940s S. aureus infections were originally treated with penicillin and later 
(1960s) penicillin-related antibiotics such as methicillin and oxacillin. However, new 
forms of the pathogen, resistant to β-lactam antibiotics (including penicillins, 
cephalosporins and carbapenams), began to emerge shortly thereafter78–80. Reports have 
shown more recent cases of resistance to other antibiotics such as erythromycin, 
fluoroquinolones, tetracycline and clydamicin81–83. Vancomycin is now the drug of choice 
to treat an MRSA infection, but a decreased susceptibility to this drug is also on the rise.  
This form is known as vancomycin resistant Staphylococcus aureus (VRSA), with an 
Minimum Inhibitory Concentration (MIC) value of ≥32μg/ml rendering it completely 
resistant83. Due to its highly mutable nature the threat of pandrug-resistance (resistance 
to all current drugs) is of growing concern for MRSA, with 95% of strains no longer 
responding to first line antibiotics and increasing numbers of studies reporting resistance 
to alternatives such as vancomycin84. In recent years the percentage of invasive MRSA 
isolates has decreased in Europe, however it remains a public health priority with a third 
of European countries reporting MRSA percentages above 25% (Figure 1.2). 
1.8.2 Enterococcus faecium  
E. faecium has been listed by the WHO as a global high priority pathogen and 
mentioned in the ECDC 2016 AMR surveillance report, with between 25 and 50% of 
invasive isolates being resistant to vancomycin in the Republic of Ireland, Poland, Latvia, 
Slovakia, Romania, Greece and Cyprus (Figure 1.3)70. In the years 2013-2016 the 
percentage of vancomycin-resistant E. faecium isolated were reported to have 
significantly increased in 7 of the 25 EU/EEA countries with a reported >20 isolates per 
year70. Vancomycin remains one of the first line treatments for Enterococcal infections. 
With increasing levels of VRE strains, new and effective treatments are required. E. 
faecium has also shown high levels of resistance to aminoglycoside antibiotics such as 
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gentamicin and can be intrinsically resistant to a variety of antibiotics such as 
clindamycin, ampicillin, penicillin and cephalosporins, making their treatment more 
difficult85. Due to its resistance to a variety of antibiotics, and its easy dissemination 
within healthcare settings, E. faecium is increasingly difficult to treat and has become a 
major pathogen of concern70. 
1.8.3 Cutibacteriumutibacterium acnes 
Cutibacterium acnes, previously classed as Propionibacterium acnes, is a Gram-
positive, aerotolerant, commensal human skin bacterium that contributes to the 
development of acne86. Although not as urgent a threat as MRSA and VRE, C. acnes 
affects 80% to 90% of the population at some stage in their life, and is the primary reason 
for dermatologist visits87,88. C. acnes is a normal part of the healthy skin flora, however 
it is an opportunistic pathogen contributing to the skin disease acnes vulgaris.  
Recent studies have shown that the increased proliferation of C. acnes itself may 
not be the direct cause of acne, but rather the loss of skin microbial diversity and the 
activation of innate immunity triggered by the colonisation of C. acnes within the 
pilosebaceous follicle results in the subsequent development of acne89. Other studies 
reporting the increasing emergence of C. acnes resistant to various antibiotics, including 
fluoroquinolones, macrolides, erythromycin, clindamycin, tetracycline and trimethoprim-
sulfamethoxazole have made this pathogen a cause for concern90–92. To date C. acnes 
remains susceptible to -lactam antibiotics, including penicillin. However, the 
development of resistance either through the alteration of penicillin binding proteins 
(PBPs) or horizontal gene transfer remains a possibility. In a recent study a strain of C. 
acnes containing the -lactamase gene was identified, which is not normally associated 
with Gram-positive bacteria, suggesting that it may be possible for the strain to acquired 
resistant to -lactam antibiotics93. Consistent use of antibiotics, such as penicillin, also 
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increases the risk of other skin species developing resistance, exacerbating the overall 
antibiotic resistance crisis94. 
1.8.4 Corynebacterium xerosis 
C. xerosis is a commensal bacteria found on human skin and mucous membranes 
and rarely causes infections of any clinical relevance, however there have been reports of 
the bacteria causing endocarditis in immunocompromised patients, postoperative 
infections and it also contributes to strong underarm odours95–98. Previous studies have 
shown that C. xerosis is growing in resistance to various antibiotics including -lactams, 
aminoglycosides, macrolides, ciprofloxacin, chloramphenicol and tetracycline98,99. One 
study reports the finding of a multiply resistant strain shown to be the cause of 
mediastinitis (inflammation of the chest cavity) in a 69-year old asthmatic patient98.  
1.9 Bacteriocins as alternative therapeutics for bacterial infections 
 With the rapid evolution of resistance a growing number of skin and soft tissue 
infections are becoming increasingly difficult to prevent and/or treat, which has prompted 
research into viable alternative therapeutics, such as bacteriocins8. Bacteriocins have 
many benefits including low toxicity, amenability to bioengineering, low level of 
resistance occurrence, broad-spectrum antimicrobial activity, and have exhibited high 
levels of potency in vitro and significant activity against pathogens in vivo, suggesting 
that they may provide a possible alternative to antibiotics23. In one study the natural nisin 
variant, nisin F, demonstrated antimicrobial activity against S. aureus within the 
respiratory tract of rats when administered intranasally100. Another study exhibited the in 
vivo activity of the lantibiotic mutacin B-Ny266, against S .aureus in a mouse model of 
intraperitoneal infection and had a median effective dose (ED50) comparable to 
vancomycin23,101.  
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 Some bacteriocins have a broad-spectrum of activity, but their overall impact on 
the composition of the human microbiota is still unclear. Conventional antibiotics with 
broad spectrum ranges have been shown to  cause damage to commensal populations 
which can be important for human health102. Numerous bacteriocins have demonstrated 
a broad-spectrum of activity, but one bacteriocin, Thuricin CD, has shown promising 
narrow-spectrum results against C. difficile. Post-treatment with thuricin CD the 
commensal microbiota in a human distal colon model was maintained, which suggests 
that there may be advantages to using narrow-spectrum bacteriocins103,104. 
 The mechanism of antimicrobial activity varies between bacteriocins. Knowing 
the specific mechanism of action for a bacteriocin is an advantage when determining 
possible targets and conducting combination studies. As discussed previously, class I 
bacteriocins, such as nisin, act by targeting lipid II of Gram-positive targets and inhibiting 
peptidoglycan synthesis thus resulting in pore formation. However, other bacteriocins 
such as lactococcin A have shown activity against Gram-positive targets by binding to 
the pore-forming receptor mannose-phosphotransferase system (Man-PTS), along with 
others demonstrating activity against Gram-negative targets by interfering with  DNA, 
RNA and protein metabolism (Figure 1.4)23.  
 Bacteriocins have already demonstrated their therapeutic potential in a 
commercial setting in animals, with nisin being the active agent in the mastitis prevention 
product Wipe Out (ImmuCell Corporation) and with thiostrepton in combination therapy 
ointments for the treatment of dermatological indications. It is clear that the use of 
bacteriocins in a clinical setting for humans is highly plausible23. Furthermore, as 
mentioned previously in the cases of nisin and lacticin, combining bacteriocins with other 
therapeutics may yield synergistic effects due to differences in mechanism of action9. 
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1.10 Cancer 
With over 200 types of cancer and approximately 14.1 million new cases reported 
globally each year, it is not surprising that cancer is one of the most extensively 
researched areas in medicine105. In 2018 cancer will be responsible for an estimated 9.6 
million deaths globally. In recent years, the number of global diagnoses has steadily 
increased and is expected to rise to 23.6 million new cases by the year 2030105. This 
increase is due to a number of factors which include a globally aging population, obesity, 
unhealthy diet with low fruit and vegetable intake, UV exposure, alcohol use, sexually 
transmitted infections, tobacco smoking and environmental factors, among others106–109. 
Other factors such as HIV/AIDS, immune factors, and organ transplantation have been 
shown to increase the risk of developing cancer due to patients having a compromised 
immune system110. Some countries have seen a decrease the number of cancer related 
deaths. In the U.S.A. for example the number of cancer incidence and related deaths has 
decreased from the years 1992 -2015 by 17% and 25% respectively, with an overall 
survival rate of 66.9% in 2014111. According to the World Health Organisation (WHO), 
1 in 6 mortalities are attributable to cancer, making it the second leading cause of death 
worldwide, with an estimate of 9.6 million deaths109. In addition, the global economic 
impact of cancer is also increasing. In 2010, the total annual economic cost was estimated 
at US$1.16 trillion109. 
Traditionally the methods used to treat cancer include chemotherapy, 
radiotherapy, chemo-radiotherapy and surgery. They are known to have a variety of side 
effects ranging in severity including, but not limited to, nausea/vomiting, hair loss, weight 
loss/gain, neutropenia, stomatitis, diarrhoea, and aggravated insomnia112–114. With this 
being said, emphasis is now on the development of therapeutics that are safe and effective 
with fewer side-effects.  
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1.11 Colorectal cancer 
In 2018 colorectal cancer (CRC) is estimated to have the third highest incidence 
rate of all cancers, approximately 1.8 million cases, and the second highest mortality rate 
with 862,000 deaths (8.98% of all cancer related deaths) (Figure 1.5)109. 
Adenocarcinomas account for approximately 96% of all CRCs and affect the mucus 
forming cells that aid in the internal lubrication of the colon and rectum115. Most CRC 
develop from a polyp, a growth on the inner lining of the colon or rectum, but not all 
polyps become malignant. Although individuals with colorectal cancer may not always 
develop symptoms some of the most common include: bloody stool, persistent stomach 
pains and unexplained weight loss116. 
1.11.1 Causation and Risk Factors 
It is estimated that in 2018 CRC incidence was more common in males than 
females worldwide, 1,026,215 and 823,303 respectively, although it has the second 
highest incident rate of any cancer in females and third in males117. Recent findings 
suggest that “Western” populations and countries experiencing a rapid societal and 
economic transition are most at risk due to changes in dietary, reproductive and hormonal 
factors118. In the U.S.A. alone the lifetime risk of developing colorectal cancer is 
approximately 4.5% for men and 4.2% for women119. However, with an aging population 
the risk of developing CRC increases with advancing age, with 90% of cases occurring 
in patients 50 years or older. A diet low in fruits and vegetables, excessive weight and 
lack of exercise are three strongly linked risk factors to CRC. Diets low in fruits, 
vegetables and fibre, and high in fat, alcohol and red meat, are known risk factors of CRC, 
with lack of regular exercise and a high Body Mass Index (BMI) contributing to the 
risk120.  
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Other factors such as tobacco use, inflammatory bowel diseases, for example 
Crohn’s disease, and having a personal or family history of CRC can also increase the 
incidence120. Genetic syndromes such as hereditary non-polyposis colorectal cancer 
(HNPCC) and familial adenomatous polyposis (FAP) account for a minority of cases121.  
In patients with FAP, multiple polyps can develop in the colon and/or rectum and 
can become cancerous over time unless the colon is removed. FAP can take three 
variations; classic, attenuated or autosomal recessive FAP. In patients with classic FAP 
polyps can form as early as their teenage years and become cancerous under 40 years of 
age121. The onset of cancer in patients with an attenuated form of FAP is on average 55 
years of age121. In the case of autosomal recessive FAP typically fewer polyps develop 
(less than a hundred, rather than hundreds or thousands) and is subsequently less 
detrimental. 
 HNPCC is a hereditary disorder that increases the risk of many cancers, 
but particularly colorectal. HNPCC develops when mutations occur within certain genes 
involved in DNA repair (MLH1, MSH2, MSH6, PMS2 or EPCAM), which can lead to 
uncontrolled cell growth, and later cancer122. However, not all individuals that have 
mutations within these genes develop cancer122. 
1.11.2 Treatment 
 The course of treatment for CRC depends greatly on the cancer stage at the time 
of diagnosis. There are a number of treatment options available including: surgery, 
radiofrequency ablation, cryosurgery, chemotherapy, radiation therapy and 
immunotherapy123. Surgery is the most common treatment at any stage of CRC. A local 
excision surgery can be used for smaller early stage cancers, and resection by either a full 
or partial colectomy (removal of the cancerous tissue along with a small amount of 
surrounding healthy tissue) for larger tumours123. Due to a high recurrence rate, 30-40%, 
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adjuvant chemotherapy or radiation therapy are often used post operation to eliminate any 
remaining cancer along with reducing the risk of recurrence124. In rectal cancers, 
depending on the tissue type and stage of disease at diagnosis, a complete removal of the 
mesorectum is standard surgical procedure, followed by adjuvant chemotherapy and 
radiotherapy125. 
 Chemotherapy drugs can be administered systemically (taken orally or injected 
into a vein or muscle to reach the blood stream) or regionally (administered directly into 
cerebrospinal fluid, organ or body cavity). Common chemotherapy drugs used to treat 
colorectal cancer include: 5-fluorouracil (5-FU), oxaliplatin and leucovorin (LV). 5-FU 
metabolises 5-fluoro-2’-deoxyuridine-5’-monophosphate, which inhibits the enzyme 
thymidylate synthase, depleting thymidine triphosphate and resulting in the termination 
of DNA synthesis. It also incorporates itself into RNA, where it inhibits RNA processing 
and subsequently cell growth, making it the primary therapy used for metastatic CRC 
(mCRC)126,127. Combination studies using 5-FU and multiple other chemotherapy drugs 
have shown great success. With overall response rates to 5-FU in late stages of CRC of 
10-15%, combination treatments are employed using oxaliplatin which demonstrate 
improved effectiveness, but at the cost of increased toxicity128. Treatment with adjuvant 
5-FU improves survival, demonstrating better results in stage III than in stage II disease, 
and is routinely used in combination with oxaliplatin for stage III disease, although 
efficacy versus toxicity levels must be closely monitored129. When 5-FU and oxaliplatin 
are used in combination, treatment time can be reduced, in some cases from 6 months to 
3 months depending on the individual, which can aid in the control of toxicity levels130. 
For individuals who have recurrent colorectal cancer; local or distant, surgery and 
chemotherapy are often the treatment of choice. In addition, chemotherapy can also be 
used to palliatively treat metastatic cancer, to improve survival, lessen symptoms and 
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improve overall quality of life. 5-FU is commonly used with oxaliplatin and irinotecan as 
a palliative therapy and can increase survival by almost 3 years127,129.  
Immunotherapy involves components of the immune system such as antibodies, 
cytokines and dendritic cells, along with vaccines to kill tumour cells. Immunotherapy 
provides a form of therapy that specifically targets tumour cells131,132. Unlike other forms 
of cancer therapy, immunotherapy has not yet provided major advances in CRC treatment 
as it has for other forms of cancer, however some therapies have shown promise132. 
Pembrolizumab, a monoclonal antibody (mAb) has demonstrated a significant effect 
against CRC tumours which resulted in it being approved by the FDA as a treatment for 
CRC132. The FDA has also approved the use of multiple monoclonal antibodies for use 
in colon cancer including, Bevacizumab (Avastin), Cetuximab (Erbitux) and 
Panitumumab (Vectibix). Bevacizumab, first introduced in clinical trials in 1997, is a 
relatively non-toxic monoclonal antibody drug that targets vascular endothelial growth 
factor (VEGF)127. VEGF is involved in controlling angiogenesis, the growth of blood 
vessels which in turn allows for proliferation of tumour cells, and high levels are 
associated with metastatic disease127. Bevacizumab is an angiogenesis inhibitor and acts 
by binding and neutralising VEGF. Bevacizumab has also been used in combination with 
specific chemotherapy regimens, for example 5-FU/LV, and has demonstrated significant 
improvement in the median survival and disease progression times of mCRC 
patients127,133. However, the use of bevacizumab has been associated with perforation of 
the bowel, in approximately 1.7% of patients134. Cetuximab and Panitumumab both target 
epidermal growth factor receptor (EGFR), a protein over expressed in 60%-80% of 
tumours and associated with tumour growth135. 
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1.11.3 Survival 
Although the survival rate has increased in recent decades, CRC remains the third 
most commonly diagnosed cancer in men and second in women109,119,125,136. The 
prognosis for a patient can range from a five year survival rate as high as 92% to as low 
as 10%, and is highly dependent on the stage of disease at diagnosis137. Typically, CRC 
has a 5-year survival rate of 90% when detected at the localised stage, 70% for regional, 
to 10% for distant mCRC137. As with most cancers, the earlier the diagnosis, the higher 
the chance of survival. Age also plays a role, with younger individuals generally 
displaying better survival rates. The 5-year survival rate for younger patients (15-45 years 
of age) can be as much as 15% higher than that for older patients138.  
In the USA CRC mortality rates have declined since 1970 by approximately 52% 
among both men and women, which is most likely attributed to improved treatments and 
increased screening. However, mortality rates of individuals less than 55 years of age 
increased by approximately 9% from 2006 to 2015139. Without treatment patients with 
advanced CRC have a median survival time of 5-6 months, and with 5-FU chemotherapy 
based treatment approximately 10-12 months, with less than 5% surviving beyond 5 
years138. In the European Union member states CRC mortality fell by approximately 13% 
in men and 27% in women from the years 1989 to 2011 compared to 39.8% and 38.8% 
in the U.S.A.140. In contrast, there have been rapid increases in in CRC incidence and 
mortality rates in many eastern European countries125. 
1.12 Oesophageal cancer 
OC is a notoriously aggressive and invasive form of cancer with 20-30% of 
patients exhibiting distant metastases at the time of initial diagnosis141. To date 
oesophageal cancer (OC) globally has the seventh highest incidence rate of all cancers, 
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approximately 572,034 cases, and the sixth highest mortality rate with 508,585 (5.3%) 
deaths (Figure 1.5)109. OC incidence is more common in males than females worldwide 
(399,699 and 172,335, respectively) with the vast majority of OCs being either squamous 
cell carcinomas (SCC) or adenocarcinomas (AC)117. Both forms are extremely aggressive 
and associated with high mortality rates142. SSC affects the cells comprising  the inner 
lining of the oesophagus and tend to develop in the upper and middle section of the 
oesophagus, and is the most prevalent form of OC worldwide143. ACs develops in gland 
cells, which in the case of OC are involved in producing mucus in the lining of the 
oesophagus, and are typically associated with the lower part of the oesophagus 
Adenocarcinomas are  the most common type of OC reported in the U.S.A.143,144. 
Incidences of OC have been increasing steadily since the 1960s/1970s and are expected 
to increase even further in the future. In 2014 it was estimated that by the year 2025 the 
prevalence of OC will increase by 140%141.  
As with other forms of cancer, an aging population is a contributing factor to 
tumour development with 80% of oesophageal cancers developing in people aged 60 or 
older145. Although individuals with OC may not always develop symptoms, some of the 
most common include: dysphagia (difficulty swallowing), chest pain, coughing and 
unexplained weight loss. 
1.12.1 Causation and Risk Factors 
Many studies have reported alcohol as the primary risk factor for the development 
of oesophageal malignancy, along with the impact of tobacco use. Reports have also 
suggested that alcohol and smoking can act almost synergistically to increase the risk141. 
Alcohol is a known solvent of many of the hazardous carcinogens within tobacco, thus 
allowing them to penetrate the oesophagus epithelium easier141. It is also notable that 
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exposure to risk factors can be linked to geographical and racial differences, with an 
incidence rate of three times higher in black individuals than white141,146.  
 Another major risk factor for OC is the presence of Barrett’s oesophagus, a 
condition involving the replacement of normal flat oesophagus squamous cells to 
abnormal columnar cells (dysplasia). Up to 5% of all individuals with Barret’s 
oesophagus go on to develop adenocarcinoma at some stage147. Males, especially 
Caucasian males, are 2-3 times more likely to develop Barrett’s oesophagus than females, 
putting them at a higher risk of developing OC148. Acid reflux is a major cause of Barrett’s 
oesophagus and can be exacerbated by smoking, consuming spicy or fatty foods, 
excessive alcohol intake and obesity147. Gastroesophageal reflux disease (GERD) has 
been shown to increase the risk of developing Barrett’s oesophagus with individuals 
diagnosed with GERD being 6-8 times more likely to have Barrett’s oesophagus148,148. 
 Other risk factors include lack of fruits and vegetables in the diet, regularly 
consuming very hot liquids, and undergoing radiation treatment for other cancers to the 
chest or upper abdomen145. Tylosis with oesophageal cancer is a genetic condition 
characterised by non-epidermolytic palmoplantar keratoderma and a lifetime risk of 
developing oesophageal SSC of up to 95% by the age of 65149. It involves the thickening 
of the palms of the hands and soles of the feet but can also result in the thickening of the 
oral mucosa149. 
1.12.2 Treatment 
 Treatment strategies for oesophageal cancers are dependent on the tumour staging 
at the time of diagnosis. When surgical resection alone is used to manage local SSC and 
adenocarcinomas of the oesophagus,  survival rates are generally low and metastatic 
recurrence levels are high150,151151. These patterns prompted the use of multimodal 
approaches. For locally advanced OC, surgery is generally used with curative intent for 
 35 
patients suitable for resection, with neoadjuvant treatment strategies if required. 
Neoadjuvant therapies (preoperative) normally consist of either chemotherapy, radiation 
therapy or a combination of both, and are used primarily over adjuvant therapy 
(postoperative)151. The majority of patients receive neoadjuvant chemotherapy, with 
therapies often including oxaliplatin/5-FU regimes141,152. One study, using 5-FU and 
cisplatin as a neoadjuvant chemotherapy regime, resulted in an improved 2-year survival 
rate, when compared to surgery alone; 43% and 34% respectively150. The use of radiation 
therapy in combination with chemotherapy (chemoradiotherapy) at the preoperative stage 
is still controversial along with the use of adjuvant chemotherapy. Recent reports suggest 
the use of neoadjuvant chemotherapy alone and to reserve the use of adjuvant 
chemotherapy for rare and select patients151. Studies conducted by the Japan Clinical 
Oncology Group compared the results of three approaches; using surgery alone, 
neoadjuvant chemotherapy, and postoperative adjuvant chemotherapy in patients with 
SCC; using cisplatin and 5-FU chemotherapy regimes153. In these studies the overall 5-
year survival did not differ significantly between patients who received postoperative 
chemotherapy compared with surgery alone (52% versus 61%), but disease-free survival 
was improved153. These studies also reported an increased 5-year survival rate when 
neoadjuvant chemotherapy was used in comparison to postoperative chemotherapy, 60% 
compared to 38%, respectively153. Other studies compare the use of chemoradiotherapy 
alone or as a neoadjuvant therapy. In one such study, involving oesophageal SSC, the 2-
year survival rates were similar in neoadjuvant chemoradiotherapy (39.9%) and 
chemoradiotherapy (35.4%) patients153.  
However, each treatment modality was associated with its own set of side effects. 
Neoadjuvant chemoradiotherapy was commonly associated with increased levels of 
postoperative mortality whereas chemoradiotherapy alone had a higher rate of local 
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relapses153. However, numerous studies have shown the advantages of 
chemoradiotherapy, which remains the basic strategy for patients with locally advanced 
oesophageal SSC or adenocarcinoma141,154. Despite advances in these areas, locally 
advanced OC is still an aggressive malignancy with poor survival rates152.  
 A promising new approach to OC treatment is the use of monoclonal antibodies. 
Certain mAbs have the ability to recognise and target abnormal proteins expressed by 
cancer cells and can influence how the cancer cell functions and flag these cells to the 
immune system. Vascular Endothelial Growth Factor (VEGF), Epidermal Growth Factor 
Receptor (EGFR) and Her-2 are common targets for these mAbs. EGFR is a 
transmembrane glycoprotein with tyrosine kinase activity, which when over expressed 
significantly increases cellular proliferation, induces angiogenesis and the development 
of metastasis, and inhibits the apoptotic pathway155. Studies report it to be over expressed 
in 50-70% of OCs155.  
 Erlotinib is a monoclonal antibody that inhibits intracellular tyrosine kinase 
associated with EGFR, and induces cell cycle arrest and apoptosis. It has shown 
promising results in the treatment of unresectable or metastatic gastric or 
gastroesophageal cancers with reports of a 20% survival rate of 6.7 months156.  
Trastuzumab is a humanised monoclonal antibody that targets human epidermal 
growth factor receptor 2 (Her-2). Her-2 is over expressed in 0-56% of patients with 
oesophageal squamous cell carcinoma and 10-40% of patients with oesophageal 
adenocarcinoma and can lead to growth promotion in cancer cells157,158. Trastuzumab has 
already proven to effective against breast cancer and is sold under the name Herceptin®. 
In addition trastuzumab has exhibited promising results against oesophageal cancer cell 
lines, exhibiting a 50% reduction in Her-2 expression when compared to untreated cells, 
and a reduction in metastases in an in vivo model157. 
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1.12.3 Survival 
Oesophageal adenocarcinoma generally have a poor prognosis with a relative 5-
year survival rate of <20%, whereas squamous cell carcinoma has a relative 5-year 
survival rate of ~12%148,159. Overall OC has a relative 5-year survival rate for localised 
disease of 43%, regional disease of 23% and distant disease of 5%160.  
More than 50% of patients have either unresectable tumours or detectable distant 
metastases at the time of diagnosis161. The survival rate of patients who do undergo 
resection varies greatly depending on the stage of cancer at the time of surgery. After 
complete surgical removal of the localised tumour, the 5-year survival rate can be as high 
as 95% for stage 0 patients, and as low as 10-15% for stage III patients161. Patients 
diagnosed at stage IV disease are not suitable for surgical treatment and are treated 
palliatively, with a median survival rate of <1 year162. 
1.13 Modes of cancer cell death 
Currently over 34 different modes of cell death have been described163. A recent 
report categorised all 34 into four basic modes of cell death, two physiological; senescent 
death (death from cellular aging) and apoptosis, and two pathological; necrosis and stress-
induced cell death163. However, other reports have classified them based on their 
morphological appearance (which can be either apoptotic, necrotic, autophagic or mitosis 
associated), enzymological criteria, functional aspects (programmed or accidental, 
physiological or pathological) or immunological characteristics164. Here we focus on 
apoptosis, and autophagic/type II cell death, a stress-induced cell death mechanism 
closely linked to apoptosis. Both exhibit very different morphological features and 
undergo different cell death pathways (Table 3).  
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1.13.1 Apoptosis  
Apoptosis is a form of programmed cell death (PCD) that cells employ to maintain 
homeostasis. It  is a normal occurrence during cell development and aging as a means to 
control cell populations, however it can also be used to eliminate cells that have become 
damaged due to infection, or as a defence mechanism during immune reactions165. 
Apoptosis can be activated by numerous stimuli and can also result from multiple 
pathways. Chemotherapy drugs can stimulate apoptosis by damaging cellular DNA, and 
depending on the stimulant, damaged cells can undergo different apoptotic pathways. A 
study using hepatocellular carcinoma (HCC) and a range of  chemotherapeutic agents, 
demonstrated that certain drugs, such as bleomycin, can stimulate a p53 dependent 
pathway, and subsequently either an intrinsic or extrinsic apoptosis signalling pathway166. 
At low doses anticancer treatments such as chemotherapy drugs or radiation can stimulate 
apoptosis, however, at higher concentrations they can also stimulate necrosis165,167.  
 Apoptosis is morphologically distinguishable by the presence of pyknosis 
(condensation of chromatin in the nucleus) and extensive cytoplasmic blebbing among 
others characteristics (Table 3). During apoptosis, DNA is fragmented and the chromatin 
is dispersed throughout the cell before being packaged into apoptotic bodies along with 
cytoplasm and other organelles165. This process is known as “budding”. In vivo these 
bodies are phagocytosed by immune cells, such as macrophages, and degraded165.  
 The extrinsic and intrinsic pathways are among the most predominant apoptotic 
pathways taken by cells. Both pathways involve numerous enzymes known as caspases 
and are activated by the cleavage of caspase-3 (Figure 1.6). Upon stimulation, the 
activation of one caspase activates the next, resulting in what is known as a caspase 
cascade. This proteolytic mechanism amplifies the apoptotic pathway, resulting in rapid 
cell death165. There are 14 known caspases to date, with the ten major ones being generally 
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categorised as follows: initiator caspases (caspase 2, 8, 9, 10) effector caspases (caspase 
3, 6, 7) and inflammatory caspases (1, 4, 5)165. Other apoptotic pathways have been 
identified, including multiple endoplasmic reticulum stress pathways where caspase 
cascades are activated, including caspases-12 (Figure 1.6). Each pathway requires the 
activation of either the initiator caspase -8 or -9, which subsequently results in the 
activation of the effector caspase, caspase-3. 
Phosphatidylserine is displayed externally on apoptotic cells, which allows 
phagocytes to quickly recognise them for disposal and avoid an inflammatory response165. 
Annexin V is a phosphatidylserine-binding protein and can be used for the detection of 
apoptosis165. 
 Upon initiation of the extrinsic pathway through the activation of transmembrane 
receptors, known as death ligands and receptors or death effector domain (some of the 
best characterised ligands and corresponding receptors include FasL/FasR and 
TNF/TNFR1), the receptors recruit and bind to cytoplasmic adapter proteins (FADD 
and TRADD)165,168. These adapter proteins subsequently result in the activation of 
caspase-8 (Figure 1.6)165.  
 Stimulants of the intrinsic pathway are non-receptor-mediated and produce 
intracellular signals (such as DNA damage and growth factor deprivation) that are 
mediated by the mitochondria165. Particular growth factors, hormones and cytokines are 
necessary for the suppression of certain apoptotic pathways, and in their absence, due to 
specific stimuli, apoptosis can be activated165. These are known as negative signals. 
Stimuli, such as radiation for example, can also generate positive signals that activate 
apoptosis165. Changes in the mitochondria, due to the stimuli, result in the release of pro-
apoptotic proteins, including cytochrome c, from the mitochondrial permeability 
transition pore into the cytosol165,169. The release of cytochrome c is both positively and 
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negatively regulated by the Bcl-2 family170. Cytochrome c activates Apaf-1 (apoptotic 
protease activating factor 1), and procaspase-9, thus forming a large protein complex 
known as an apoptosome, which subsequently leads to the activation of caspase-9 (Figure 
1.6)165,170,171. Other pro-apoptotic proteins are released from the mitochondria during 
apoptosis which are involved in DNA fragmentation and chromatin condensation, and are 
also regulated by members of the Bcl-2 family165,172. Tumour suppressor proteins such as 
p53 have shown to play a role in the regulation of Bcl-2, an anti-apoptotic protein173. 
There is also evidence of “cross talk” between the extrinsic and intrinsic pathways, 
involving the cleavage of the pro-apoptotic protein BID by caspase-8, leading to 
mitochondrial damage and thus apoptosis174. Once caspase-3 has been activated by an 
initiator caspase (caspase-8, -9, or -10), it in turn activates CAD, an endonuclease that is 
responsible for fragmenting DNA165,175.  
1.13.2 Autophagic / Type II cell death 
Typically, the role of autophagy is to promote cell survival under metabolic stress 
through the degradation of intracellular components and their subsequent recycling. Even 
if extracellular nutrients are plentiful, the deficiency in components such as growth factors 
can lead to the internalisation and degradation of nutrient transporters thus depriving the 
cell of nutrients176. The lack of extracellular nutrients and growth factor signalling 
stimulates apoptosis, however cells have the ability to activate autophagy in a bid to 
provide energy for mitochondrial activity and ultimately save the cell176. During 
autophagic activity, proteins, organelles and other cytoplasmic components are taken up 
into a double-membrane structure known as an autosome, which subsequently fuses with 
a lysosome to break down each component177. Furthermore, autophagic activity can be 
initiated to control the quality of cytoplasm by eliminating protein aggregates and 
damaged organelles177. 
 41 
Autophagy morphology is distinguished by large autophagic vacuoles in the 
cytoplasm and, in comparison to apoptosis, the absence of chromatin condensation (Table 
3). In contrast to apoptotic cells, autophagic cells in vivo have little to no association with 
phagocytes164.  
In addition to autophagy acting as a survival mechanism it has been suggested as 
a mode of cell death165,178. Normally autophagy precedes apoptotic cell death however 
autophagic cell death has been known to occur in situations where cells were unable to 
activate apoptosis. One study showed that in the absence of the pro-apoptotic proteins, 
BAX and BAK (important for the release of specific proteins from the mitochondria 
during apoptosis), cell death was achieved by autophagy, which is regulated by Atg5 and 
Beclin1179. Interestingly, another study showed that Beclin1 is required for both Atg5 
dependent and independent autophagy180. Additional studies, including an in vivo study, 
have been conducted showing the importance of autophagic activity for cell death, during 
Drosophila development181,182. Furthermore, reports have suggested certain cell death 
pathways are autophagy-dependent, however it is still controversial as to whether 
autophagy alone leads to cell death or facilitates other death pathways177. 
The role of autophagy in cancer is controversial. In general it functions as a 
tumour suppressor pathway by preventing tumour initiation but it can also act as a 
survival pathway taken by tumour cells to survive metabolic stress and in some cases 
resist death caused by certain cancer chemotherapy183. Indeed one commercial product 
that induces autophagic activity has been developed, tamoxifen, which exhibits 
preventative activity against breast cancers, however other agents involved in the 
suppression of autophagic activity are also undergoing clinical trials183. One study raises 
the concern of preventing autophagy-dependent anticancer immune responses and 
therefore limiting the impact of chemotherapy treatment183,184. Moreover, due to 
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autophagic activity aiding in tumour suppression, the initial benefits of suppressing 
tumour progression achieved by autophagy suppression, may lead to increased incidence 
of secondary malignancies183. 
1.14 Bacteriocins as alternative cancer therapeutics 
 As previously described, current cancer therapies have non-specific toxicity 
which affects healthy cells and causes undesirable side-effects21. Moreover, cancers have 
been known to develop resistance to certain chemotherapy drugs, accentuating the need 
for novel therapies21. In recent years several studies have begun to explore the potential 
of bacteriocins as alternative anti-cancer therapeutics21. These studies, have suggested 
that bacteriocins may be capable of selectively binding to cancer cells due to these cells 
exhibiting a different membrane fluidity to healthy cells, further accentuating their 
promise as future anti-cancer agents20,21,185.  
 A number of bacteriocins have been investigated for anti-cancer activity including 
nisin, colocins, microcins, pyocins,pediocins, plantaricin A, bovicin and smegmatocin21. 
Varying levels of anti-cancer activity were demonstrated, mainly in vitro, against a wide 
range of cancer cell lines including human colorectal cell lines ( HT29 cells)186. These 
studies are at the forefront of the exploration into the potential use of bacteriocins in 
cancer therapy. It is relevant to note that different bacteriocins will have varying effects 
on cancer cells, bactofencin for example has been shown to decrease cell proliferation of 
HT29 cells but increase cell proliferation of HCT116, Caco2, OE19 and SW620 cell lines 
(Figures A 1.2, A 1.3). The varying levels in activity suggest that more research should 
be done conducted as cytotoxicity appears to be bacteriocin and cell line dependent. 
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1.14.1 Nisin as an alternative cancer therapeutic 
 The interest in nisin over other bacteriocins is most likely due to its GRAS status 
and that it is one of the most highly researched bacteriocins to date187. It has been the 
subject of numerous studies in recent years with regards to its anti-cancer potential and 
has demonstrated cytotoxic activity against various cancer cells lines in vitro and in 
vivo22,188. Studies demonstrating nisin A’s cytotoxicity against human colon cells (SV40-
HC cells) were carried out in 2003, with percentage cell survival of <50% after 48hrs of 
treatment with all concentrations tested (170AU/ml, 350AU/ml and 700AU/ml)189. 
Further in vitro studies showed the cytotoxic effects of nisin A on two colorectal 
adenocarcinomas, HT29 and Caco2 24hrs post treatment, and one breast adenocarcinoma, 
MCF-7 48hrs post treatment, with IC50 (concentration at which half of the cells are 
inhibited) MTT values of 89.9M, 115.0M and 105.46M, respectively190,191. 
Morphological changes in nisin A treated MCF-7 cells, when compared to untreated 
controls, were observed through microscopic examination including vacuolization of the 
cytoplasm, cell shrinkage, condensation and lateralisation of the nucleus which may 
suggest death by apoptosis but in the presence of autophagic activity191. 
 A more recent in vitro and in vivo study investigated the cytotoxic and anti-tumour 
properties of nisin A against head and neck squamous cell carcinoma (HNSCC)22. The 
study demonstrated nisin A’s ability to lessen HNSCC tumorigenesis via CHAC1, a 
proapoptotic cation transport regulator, and a contributing CHAC1-independent influx of 
extracellular calcium22. It has been suggested that the ability of nisin to differentially alter 
the transmembrane potential and membrane composition of HNSCC cells in comparison 
to the primary keratinocytes, may be due to differences in the structure and function of 
their lipid membrane and response to calcium influxes, and that this may be the reason 
for its preferential anti-cancer activity8. Apoptosis was induced along with reduced 
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HNSCC cell proliferation, and cell cycle arrest when treated with 80g/ml nisin22. The 
study also included an in vivo oral xenograft mouse model whereby nisin significantly 
reduced tumorigenesis22. 
 A later study was completed using nisin ZP, with a higher active content of 95%, 
for the treatment of HNSCC in both in vitro and in vivo mouse models192. The data 
supported the potential use of nisin as an alternative therapeutic by demonstrating an 
increased level of apoptosis, and decreased levels of cell proliferation, clonogenic 
capacity and sphere formation in HNSCC cells. In addition, long-term treatment with 
nisin ZP extended survival in mice with normal organ histology and no evidence of 
inflammation, fibrosis or necrosis192. 
 The use of bacteriocins in conjunction with currently used anti-cancer drugs was 
also investigated in a recent study demonstrating the potential benefits of combining nisin 
with the anti-cancer drug cisplatin. Synergistic activity was observed between  nisin and 
cisplatin when used to treat HNSCC cells that are normally highly resistant to cisplatin 
and ionizing radiation188. Furthermore, the addition of nisin was shown to increase the 
effectiveness of doxorubicin treatment, evident by the in vivo reduction of tumour severity 




 The growing concern of antibiotic resistance highlights the need for alternative 
therapeutics. The assessment of different antimicrobials, such as bacteriocins, in 
therapeutic strategies, as sole agents or in combination, allows for the reassessment of 
how conventional antimicrobials are currently used in therapeutic regimes. With 
lantibiotics presenting a naturally low occurrence of antibiotic resistance these modified 
peptides may serve as an alternative to or could be used in conjunction with conventional 
antibiotics. In addition, bioengineering techniques have aided in the identification of the 
structure and function of various peptides, and to the creation of new variables with 
enhanced activity and stability. Further manipulation of such peptides could lead to future 
tailoring of genetic variants to help overcome issues such as resistance. 
 Cancers of the gastrointestinal system, particularly those of the oesophagus and 
colon, are known for their late detection and poor prognosis with therapeutic regimes 
often accompanied by multiple adverse effects. The use of bacteriocins may offer an 
alternative approach to anti-cancer treatments, having shown effectiveness against a 
variety of cancers in vitro and in vivo with little to no adverse effects.  
 In conclusion, bacteriocins may have multiple biomedical applications in the 
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• Multidrug-resistant Acinetobacter 
• Drug-resistant Campylobacter 
• Fluconazole-resistant Candida  
• Extended spectrum beta-lactamase-
producing Enterobacteriaceae 
(ESBLs) 
• Vancomycin-resistant Enterococci 
(VRE) 





resistant Salmonella ttyphimurium 
• Drug-resistant Shigella 
• Methicillin-resistant Staphylococcus 
aureus (MRSA) 
• Drug-resistant Streptococcus 
pneumoniae 
• Drug-resistant tuberculosis 
• Erythromycin-resistant 
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Antibiotic resistant pathogenic bacteria 
• Escherichia coli 
• Klebsiella pneumoniae 
• Pseudomonas aeruginosa 
• Acinetobacter species 
• Streptococcus pneumoniae 
• Methicillin-resistant Staphylococcus 
aureus(MRSA) 
• Enterococci (including E. faecium 
and E. faecalis,  




















Cell death mode Morphological features 
Apoptosis 
Reduction of cellular and nuclear volume (pyknosis) 
Nuclear fragmentation (karyorrhexis) 
Minor modification of cytoplasmic organelles 
Plasma membrane blebbing 
Engulfment by resident phagocytes, in vivo 
Autophagy 
Lack of chromatin condensation 
Massive vacuolization of the cytoplasm 
Accumulation of (double-membraned) autophagic vacuoles 
Little or no uptake by phagocytic cells, in vivo 
Necrosis 
Cytoplasmic swelling (oncosis) 
Rupture of plasma membrane 
Swelling of cytoplasmic organelles 
Moderate chromatin condensation 











































Figure 1.3 Percentage of invasive vancomycin resistant E. faecium isolates in the 





















































Figure 1.6 Apoptosis pathways adapted from John C. Reed and Maurizio Pellecchia, 
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Analysis of nisin-AAA induction properties by mutagenesis of K12 and H31 
 






Nisin is a ribosomally synthesised Class I lantibiotic produced by Lactococcus 
lactis and is one of the most studied bacteriocins to date, largely due to its importance as 
a preservative within the food industry. Nisin is amenable to bioengineering due to its 
gene-encoded nature, and various studies have utilised this characteristic to create 
mutants with improved properties. In this study we started with an already created nisin 
variant termed nisin-AAA (nisin A with three Alanines (A) replacing the normal residues 
at positions 20, 21 and 22) and created a bank of variants with substitutions at positions 
12 (Lysine 12, K12) and 31 (Histidine 31, H31). Substitutions were made both 
independently and in combination in an effort to determine the impact of each amino acid 
change on the ability of nisin to induce the PnisA promoter (self-induction is an important 
property of nisin). We identified ten variants that retained the ability to induce PnisA  
(K12K/H31H, K12V, K12Q, K12W, K12T, K12A, K12C, H31N, H31K and H31R). 
Further analysis suggested a role for amino acid charge on the peptides’ induction 
capabilities. We also showed that six variants could not induce PnisA, but were able to 
maintain induction once triggered by another peptide (K12M, K12I, K12L, K12R, K12S 
and K12Y). One mutant, K12V-AAA-H31V, which had previously been shown to be 
resistant to degradation by the proteases trypsin and chymotrypsin, also demonstrated loss 
of induction. With N, K and R representing known cut sites for trypsin or chymotrypsin 
and amino acid substitutions H, R, N and K at position 31 being the only substitutions 
capable of maintaining auto-induction, our results suggest that any substitution at position 




Nisin A is a pentacyclic antimicrobial peptide that is ribosomally-synthesised by 
some Lactococcus lactis strains and which displays broad antimicrobial activity against 
Gram-positive bacteria1. This 34 amino acid bacteriocin is categorised as a Class I 
lantibiotic, due to the presence of one lanthionine and four methyllanthionine amino acid 
residues1. These unusual amino acids are a result of post-translational modifications 
which are enzymatically introduced when a covalent bridge is formed between a 
dehydrated serine (S) or threonine (T) residue and a cysteine (C) residue to become 
dehydroalanine (Dha) or dehydrobutyrine (Dhb), respectively1. 
  The successful production of the mature nisin peptide is reliant on the inter-
communication of several proteins and genes, and the mature peptide plays a role in its 
own induction through the specific activation of a number of these genes1–4. The 
transmembrane histidine protein kinase (HPK), NisK, is capable of detecting and binding 
the nisin peptide. This binding, involving the N-terminal ring structures of nisin, 
subsequently activates the intracellular response regulator, NisR, which in turn triggers 
the activation of the nisA promoter (PnisA) on the nisin operon (Figure 2.1)1–5. In order to 
form the mature peptide, a precursor form of nisin with an N-terminal leader is first 
translated before being post-translationally modified. At this stage, selected S and T 
amino acids are dehydrated by NisB and lanthionine bridges are formed by NisC. The 
peptide is subsequently exported out of the cell by NisT and cleaved of its N-terminal 
leader by NisP. The resulting peptide is fully mature and can now interact with NisK 




Figure 2.1 Nisin auto-induction loop schematic, adapted from Mierau et al., 
20056. 
 
For many years this nisin auto-induction mechanism, termed the Nisin-Controlled 
gene Expression (NICE) system, has been exploited for the expression of numerous 
genes. A gene of interest can be placed behind the inducible promoter PnisA on a plasmid 
or the chromosome and, so long as NisRK are present, will be expressed when induced 
by the addition of sub-inhibitory amounts of nisin (0.1-5ng/ml)6. NZ9000 is the most 
commonly used host strain and has the signal transduction genes, nisK and nisR integrated 
into the pepN gene on the chromosome of MG1363 (nisin negative and plasmid free L. 
lactis subsp. cremoris)3,6,7.  
 Its wide-ranging potential as a biological therapeutic has sparked interest in 
creating novel variants of nisin with higher activity, stability and solubility through 
bioengineering8,9. Due to their gene-encoded nature, many lantibiotics, including nisin, 
can be readily manipulated. In a previous study the amino acids asparagine (N), 
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methionine (M) and lysine (K) (referred to as the ‘hinge’ region between the N and C 
domains, located at residues 20-22) were changed to three alanine residues (AAA), 
resulting in a peptide with enhanced bioactivity against the bacterial strains Lactococcus 
lactis HP, Streptococcus agalactiae ATCC 13813, Mycobacterium smegmatis MC2155 
and Staphylococcus aureus RF12210. A further study using this mutant (nisin-AAA) 
involved the alteration of the remaining cut sites for trypsin and chymotrypsin, thereby 
engineering the nisin-AAA mutant to become trypsin and chymotrypsin resistant. Several 
of these trypsin and chymotrypsin resistant variants lost their ability to induce PnisA11. 
The nisin-AAA variant formed the basis of this study. A new round of genetic 
engineering was employed to generate 38 derivatives of nisin-AAA with all possible 
individual amino acid changes at positions K12 and H31 (Figure 2.2). In this study we 
examined the ability of these nisin variants to activate the auto-induction loop. 
 
Figure 2.2 Nisin-AAA structure, consisting of the amino acid sequence of nisin A with 
the hinge region changed from NMK to AAA (highlighted in red), and the location of its 
five lanthionine rings and modified residues dehydroalanine and dehydrobutyrine. 
Positions K12 and H31 are boxed in red and show all amino acid changes made at these 
positions.  
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1.19 Experimental Procedures 
 
1.19.1 Bacterial strains and growth conditions 
The chemically competent E. coli Top 10 (Invitrogen) host strain was grown in 
Luria-Bertani (LB) broth or agar and incubated at 37C. Lactococcus lactis strains 
(obtained from UCC culture collection) were grown in GM17 broth or agar (1.5% agar) 
(Oxoid) supplemented with 0.5% glucose and incubated at 30C (Table 2.1). Tryptone 
yeast (TY) broth, used for peptide purification, was comprised of 3.125mg/ml Tryptone, 
6.25mg/ml yeast extract, 62.5mg/ml manganese sulphate and 156.25mg/ml magnesium 
sulphate. In the incidences where chloramphenicol (CM) was required, a concentration 
of 10g/ml was used for E. coli and 5g/ml for L. lactis.  
 
1.19.2 Site-saturation mutagenesis of the nisin-AAA K12X and H31X regions 
  Initially, the plasmid pDF05-AAA was extracted (using GeneJET plasmid mini 
Prep Kit, Thermo Scientific) from E. coli Top10 (Invitrogen), to ensure its methylation, 
and used as the template to make the separate targeted changes at positions lysine 12 
(K12) and histidine 31 (H31) by means of randomized, site-saturated mutagenesis10. 
Phusion PCR was performed using primers NisK12degFOR and NisK12degREV, and 
NisH31degFOR and NisH31degREV (Table 2.2). PCR amplification was executed in a 
total of 50l comprised of 2U/µl of Phusion High Fidelity DNA Polymerase (Novagen), 
~50ng target DNA, 10X GC buffer, 10mM dNTPs and 200ng of the relevant 
oligonucleotides (Table 2.2). Cycling conditions were as follows: pre-heated at 98C for 
30secs, 98C for 10secs, 67C for 30secs and 72C for 4.5mins for 34 cycles followed by 
a 72C extension time for 10mins. The amplified product was treated with Dnp1 
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(Stratagene) along with buffer (UniV10X) at 37C for 1hr to ensure the complete digest 
of parental DNA. A GeneJet PCR Purification Kit (ThermoFisher Scientific) was used to 
clean the PCR product and remove any remaining impurities. 2µl of mutated pCI372-
NisAAA was introduced into Top10 chemically competent E. coli cells (Invitrogen) and 
plated on LB CM10 agar. To determine if the correct rate of mutation had been achieved, 
transformant colonies on LB CM10 agar were pooled (K12X and H31X transformants 
pooled separately) before isolating and sequencing recombinant plasmid DNA using 
primers pCI372FOR and pCI372REV (Table 2.2). Plasmid DNA was subsequently 
introduced by electroporation into electro-competent L. lactis MG1363. To identify 
specific amino acid changes the transformants were selected for on GM17 CM5 agar and 
sent for sequencing (Source bioscience, Waterford, Ireland). Individual colonies were 
added to GM17 in 96-well microtiter plates and incubated over night at 30C before 
adding 80% glycerol (Sigma Aldrich) and storing at -20C. As many amino acid changes 
as feasible were made at positions K12 and H31 using this method, and the remaining 
variants were generated using site-directed mutagenesis (Table 2.2). 
 
1.19.3 Site-directed mutagenesis of the nisin-AAA K12X and H31X regions  
Remaining variants were generated through site-directed mutagenesis (K12P, 
K12F and K12M). Individual oligonucleotides were designed for each amino acid change 
and a 50l Phusion PCR reaction was completed using the method as described above. 
The individual mutants were subsequently transformed into E. coli and L. lactis NZ9800 
using the methods as described above. 
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1.19.4 Mass spectrometry 
For Colony Mass Spectrometry (CMS) bacterial colonies were collected with 
sterile plastic loops and mixed with 50µl of 70% isopropanol adjusted to pH2 with HCl. 
The suspension was vortexed, the cells centrifuged at 14,000rpm for 2mins, and the 
supernatant removed for analysis. Mass Spectrometry in all cases was performed with an 
Axima CFR plus MALDI TOF mass spectrometer (Shimadzu Biotech, Manchester, UK). 
A 0.5µl aliquot of matrix solution (alpha-cyano-4-hydroxy cinnamic acid (CHCA), 10mg 
ml−1 in 50% acetonitrile-0.1% (v/v) trifluoroacetic acid) was placed onto the target and 
left for 1–2mins before being removed. The residual solution was then air-dried and the 
sample solution (re-suspended lyophilised powder or CMS supernatant) was positioned 
onto the pre-coated sample spot. Matrix solution (0.5µl) was added to the sample and 
allowed to air-dry. The sample was subsequently analysed in positive-ion reflectron 
mode. 
  
1.19.5 Deferred antagonism assays 
An agar-based deferred antagonism assay was used to analyse and compare the 
induction capabilities of the 38 nisin-AAA derivatives to the original nisin-AAA. 
Nisaplin (containing 2.5% nisin A) was used to induce the production of each nisin-AAA 
variant. Each bank of producers (full K12X bank and H31X bank) was stamped, using a 
replicator, onto GM17 agar plates both with and without 2.5µg/ml Nisaplin (0.0625g/ml 
nisin A). Following incubation at 30C for 18hrs the producer plates were UV treated for 
30mins. GM17 agar (0.75% agar) was seeded with the indicator strain L. lactis HP and 
poured over the K12X and H31X producers followed by further incubation at 30C for 
18hrs (indicator strain growth conditions). The plates were examined for zones of 
clearance which indicate the susceptibility of the indicator strain to the nisin variant strain. 
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Zone size was measured using Vernier callipers and compared to the original nisin-AAA 
zone.  
  
1.19.6 Agar well diffusion assays  
4.6mm diameter wells were bored into appropriate agar that had previously been 
seeded with indicator strain at a 0.2% inoculum, and incubated at the appropriate 
temperature overnight. 20µl volumes of cell-free supernatant from overnight K12X and 
H31X nisin-AAA producing cultures were aliquoted into each well. Following 18hrs of 
incubation, at relevant temperatures, the zones produced were measured using Vernier 
callipers.    
  
1.19.7 Induction signalling restoration  
The ability of each new variant to maintain induction signalling was determined 
by growing K12X and H31X nisin-AAA producers with 2.5g/ml Nisaplin (equivalent 
to 62.5ng/ml nisin) and incubating for 18hrs at 30C using GM17 broth with 2.5g/ml 
Nisaplin (without a variant) as a negative control. Following incubation, agar well 
diffusion assays were performed using L. lactis HP as an indicator strain as described 
previously. 10l aliquots were also taken from overnight cultures and sub-cultured into 
fresh GM17 broth (without Nisaplin) and incubated for a further 18hrs at 30°C. Following 
this second incubation, a set of 10l aliquots were sub-cultured once more into fresh 
GM17 broth. Well diffusion assays were performed on each set of sub-cultured 
overnights (method described previously). Zones produced following each incubation 
were measured using Vernier callipers.   
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1.19.8 Peptide purification  
L. lactis NZ9700 (nisin A producer), or the mutant nisin strain of interest, was 
sub-cultured twice in GM17 broth at a 1% inoculum before use. Modified Tryptone Yeast 
(TY) broth was first made by supplementing TY broth with manganese sulphate 
(0.0625mg/ml) and magnesium sulphate (0.1562mg/ml) and subsequently passing the 
broth through a column (70cm length and 5cm internal diameter) packed to 1/3 its height 
with Amberlite XAD-16 beads (Sigma). Two litres of sterile modified TY broth were 
supplemented with glucose and -glycerophosphate (0.01g/ml and 0.019g/ml 
respectively) before inoculation with the prepared culture at 0.5% and incubation at 30°C 
overnight. Following overnight incubation the culture was centrifuged for 15mins at 
7000rpm. The supernatant was retained and the pelleted cells re-suspended in 300ml of 
70% HPLC-grade 2-propanol containing 0.1% v/v trifluoroacetic acid (TFA) and stirred 
at room temperature for 3hrs. Cell debris was removed by a second centrifugation at 
7000rpm for 15mins and the supernatant retained. The supernatants from the first and 
second centrifugation were combined and the volume reduced to approximately 300ml 
via rotary evaporation. The pH of the combined supernatants was adjusted to pH4 using 
sodium hydroxide (NaOH) and was subsequently passed through a 10g 60ml SPE C-18 
column (Phenomenex) that had been pre-equilibrated with methanol and water. The 
column was washed with 120ml 30% ethanol, and the final solution containing the desired 
peptide was eluted in 60ml 70% 2-propanol containing 0.1% v/v TFA.  
15ml aliquots of the final elution were concentrated through rotary-evaporation to 
approximately 2ml. 1.5ml samples were applied to a Phenomenex C12 Reverse-Phase 
(RP) HPLC column (Jupiter 4m proteo 90 Å, 250 X 10.0mm, 4m) previously 
equilibrated with acetonitrile containing 0.1% v/v TFA. The solvent gradient was 
gradually increased from 25% to 60% at 45mins at a flow rate of 1.2ml/min. The resultant 
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fractions, which were deemed to contain peptide were pooled and excess solvent removed 
by rotary evaporation. Aliquots of the final solution were freeze dried at -50°C for 
approximately 48hrs.     
 
1.19.9 Nisin induction using nisin A-GFP expression system 
Growth and fluorescence assays using L. lactis NZ9000 pNZ8150-gfp+ 
containing the gene for green fluorescent protein (GFP) were completed using a 2% 
inoculum of L. lactis NZ9000 pNZ8150-gfp+ overnight in GM17 broth CM10, followed 
by incubation for 3-4 hrs at 30°C. The OD600 was monitored to achieve an absorbance of 
~ 0.2 – 0.3.  
 For supernatant assays both banks of variants (K12X and H31X), in addition to 
the original nisin A and nisin-AAA, were propagated overnight in GM17 CM10 and 
subsequently pelleted by centrifugation. The supernatant was collected and centrifuged a 
second time. 5µl aliquots were taken from each supernatant and added to 995µl fresh 
GM17 broth containing 20µl of the L. lactis NZ9800 pNZ8150-gfp+ (OD600 ~0.2-0.3 as 
previously outlined) and briefly vortexed. 200µl of each sample was aliquoted in triplicate 
into the wells of a 96 well plate and the fluorescence monitored over an 18hr period at 
30°C using a SpectraMax MP3 spectrophotometer with an excitation/emission of 
488/510nm. Green fluorescent protein was detected in terms of relative fluorescence units 
(RFU). 
For peptide-based assays (K12V-AAA-H31V) 5l of 5ng/ml, 10ng/ml and 
100ng/ml concentrations of purified peptide were added to 995l GM17 broth containing 
20l of the L. Lactis NZ9000 pNZ8150-gfp+ (OD600 ~0.2 - 0.3) and vortexed briefly. 
200µl of each sample was aliquoted in triplicate into wells of a 96 well plate and the 




1.20.1 Generation, mass spectrometry and DNA sequencing analysis of a bank of 
nisin-AAA derivatives 
Site-saturated and site-directed mutagenesis methods were used to generate a bank 
of nisin-AAA variants in which positions K12 and H31 were individually substituted with 
all 19 alternative natural amino acids (Tables 2.1, 2.2) (Figure 2.2). Site-saturation 
mutagenesis involved using oligonucleotides to replace the specific codons (at positions 
K12 and H31) with an NNK triplet potentially encoding for all 20 standard amino acids 
(Table 2). Variants that were not recovered using this method were subsequently made 
through site-directed mutagenesis using specific oligonucleotides, making up a complete 
“K12X” and “H31X” bank of producers (Table 2.2). 
Mass spectrometry was performed on each variant to confirm each amino acid 
substitution (Tables 2.3, 2.4).  Previous studies suggest that T and S, not normally present 
in mature nisin because of dehydration by NisB, retain the potential to be modified when 
introduced at positions 12 and 31, and can be dehydrated to form dehydroalanine (Dha) 
and dehydobutyrine (Dhb)12. In the presence of a C residue, intramolecular cross-links 
can occur covalently linking Dha or Dhb residues to C, thus forming lanthionine rings4,13–
15. Analysis of K12S, K12T, H31S and H31T derivatives by colony mass spectrometry 
(CMS) confirmed these modifications occurred to some degree, with masses 
corresponding not only to unmodified S and T but also masses indicating the presence of 
Dha and Dhb respectively. In the case of derivative K12C the mass detected does not 
correspond to the calculated unmodified mass, thus indicating that the newly incorporated 
C has been modified. Also in line with results from previous studies, the variant K12D 
did not produce a corresponding mass13. DNA sequencing analysis confirmed that all 40 
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variants had been successfully introduced at the codons for the K12 and H31 positions 
with no other alterations to the nisin gene.  
 
1.20.2 Analysis of bioactivity and self-induction of nisin-AAA bank 
The bioactivity and auto-induction ability of each variant was assessed using 
deferred antagonism assays against the target indicator strain L. lactis HP. Nisin A (in the 
form of the commercially available Nisaplin at a concentration of 2.5g/ml) was used to 
determine whether the production of each variant could be induced. In the absence of 
Nisaplin the auto-induction ability of each variant could be determined by the presence 
(retained auto-induction) or absence (lost auto-induction) of a zone of clearing (Figures 
2.3, 2.4). It was observed that 11 of the 40 variants remain capable of self-induction. All 
variants demonstrated bioactivity once induced with Nisaplin, with the exception of 
K12D (Figure 2.4). In addition, each variant produced a larger zone of clearing when 
induced by Nisaplin as opposed to induction by its own peptide. We also noted that the 
variants K12V and K12C both produced larger zones when self-induced than original 
nisin-AAA.  
 
1.20.3 Induction signalling restoration  
Well diffusion assays were performed on Nisaplin-induced (2.5µg/ml) overnight 
(18hrs) cultures of each variant. Following the initial 18hrs incubation, 10l was sub-
cultured into fresh media (10ml) and grown for a further 18hrs followed by well diffusion 
assays. A second sub-culture lowered the Nisaplin concentration to 0.0025ng/ml. Well 
diffusion assays were subsequently performed on this second sub-culture. Our results 
showed that those variants originally capable of self-induction also continued to induce 
after the second passage (variants K12K, K12V, K12Q, K12W, K12T, K12M, K12A, 
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K12C, H31H, H31N, H31K and H31R). However, six variants at the K12X position, that 
had lost their ability to self-induce following mutagenesis, were able to retain production 
once initially induced by Nisin A, and maintained this through two subcultures; K12M, 
K12I, K12L, K12Y, K12R and K12S (Figure 2.5). Twelve variants retained their 
induction after the first passage, but subsequently lost this ability at the second passage 
(Figure 2.5).  
 
1.20.4 Nisin-AAA derivative self-induction analysis using nisin GFP expression 
systems 
A green fluorescent protein (GFP) expression reporter system (L. Lactis NZ9000 
pNZ8150-gfp+ producer strain) was used to assess the induction abilities of each of the 
nisin-AAA variants (Figure 2.6)16. The highest level of fluorescence was determined for 
each variant (Figure 2.6). As expected, those variants able to self-induce also induced 
GFP expression. All K12X variants not capable of self-induction in previous assays, but 
able to retain activity after the second passage (0.0025ng/ml Nisaplin) (Figure 2.5 A), 
were also able to induce GFP production (Figure 2.6 A). Six variants that lost the ability 
to auto-induce following a second passage were still capable of inducing GFP production; 
K12H, H31Q, H31L, H31A, H31I and H31M. A lack of fluorescence signal was also 
observed in variants K12N, K12P, K12F, H31V, H31S and H31Y (Figure 2.6) which had 
lost their induction ability after the second passage (Nisaplin concentration of 
0.0025ng/ml) in the previous assay (Figure 2.5). Two variants (H31T and H31P) that lost 
induction capabilities after the first passage (Nisaplin concentration of 0.0025g/ml) 
(Figure 2.5 B), could induce GFP. It is also noteworthy that the positively charged amino 
acid changes were all able to induce GFP (Figure 2.6), even if they were not all able to 
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self-induce or retain self-induction after the second passage in the previous assay (Figure 
2.5). 
In one study variants were engineered with amino acid changes at both positions 
K12 and H31 to produce derivatives that were both trypsin and chymotrypsin resistant11. 
One of the most active variants, K12V-AAA-H31V, was evaluated in this study to 
determine its ability to maintain a self-induction loop. Simultaneously, the producing 
strain’s growth, and corresponding peptide’s ability to maintain a self-induction loop, 
were examined using absorbance growth curves and the GFP reporter system 
respectively, over 22hrs. It was observed that this variant was capable of inducing the 
production of GFP at a peptide concentration of 100ng/ml and only marginally induced 
GFP expression at a peptide concentration of 10ng/ml (Figure 2.7). When the peptide 
concentration was increased to 100ng/ml, nisin A had an extended lag time of >2hrs in 
the absorbance growth curve, which corresponds to the results observed in the GFP 
fluorescence curve (Figures 2.7 C, D), whereas the nisin K12V-AAA-H31V did not. 
When separately induced by 100ng/ml of each peptide, GFP expression reached 
approximately the same level of fluorescence (RLU) in each case albeit at different time 




Nisin has two domains, the N-terminal consisting of the A, B and C rings, and the 
C-terminal containing the D and E rings. The two domains are connected by a flexible 
hinge region, which in the nisin-AAA variant consists of three Alanines. Previous 
investigations involving nisin-AAA variants, show that selected combined amino acid 
changes at positions K12 and H31 give rise to trypsin and chymotrypsin resistance, whilst 
retaining biologically activity (one of the most active variants being nisin K12V-AAA-
H31V)11. However, an unexpected side effect was the loss of auto-induction in the 
majority of the derivatives. The aim of this study was to determine what effects amino 
acid changes at K12 and H31 had on induction by analysing the expression of each nisin-
AAA derivative in the presence and absence of Nisaplin, and also by monitoring the 
induction of a gfp+ gene translationally fused to the nisin promoter. 
 Positions K12 and H31 of the nisin-AAA variant were separately changed to every 
possible alternative natural amino acid. Sequencing of each variant was performed to 
confirm the correct amino acid substitutions, before carrying out colony mass 
spectrometry to confirm the nature of each variant. The variant K12D failed to produce a 
mass or bioactivity, even when induced (Table 2.4 and Figure 2.5 A), which is consistent 
with previous studies13,17. In the case of T, S and C substitutions, post-translation 
modifications can occur to form Dha, Dhb and possibly lanthionine rings, which in the 
case of H31T, H31S, K12T and K12C variants was evident from the CMS results (Tables 
3, 4)4,13–15. Further bioactivity assays were carried out on the K12C variant, however it 
was not more active against any indicator strains tested (with the exception of L. lactis 
HP), nor was it more soluble. 
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Determinations of the bioactivity of the variants against L. Lactis HP in the 
absence and presence of Nisaplin provided an indication of each variant’s self-induction 
properties. When induced with 2.5µg/ml Nisaplin (containing 2.5% nisin A), all variants 
other than K12D demonstrated bioactivity as indicated by the presence of a zone of 
clearing against L. lactis HP13,17,18. When allowed to self-induce, both K12V and K12C 
were the only variants exhibiting zones of inhibition larger than the original nisin-AAA, 
possibly as a result of increased production, diffusion or specific activity. In the absence 
of Nisaplin only 10 nisin-AAA variants maintained the ability to self-induce (original 
nisin K12-AAA-H31, K12V, K12Q, K12W, K12T, K12A, K12C. H31N, H31K and 
H31R). Given that K12 is conserved across all known natural nisin variants, it implies 
that this is an important position for the peptide and its production1,2. Six substitutions at 
position K12 were capable of maintaining self-induction and bioactivity (K12V, K12Q, 
K12W, K12T, K12A and K12C). The introduction of the negatively charged amino acids 
D and E at position K12 resulted in the decrease or complete loss of production and self-
induction (Figures 2.4 & 2.5). It is notable that in a previous study the nisin A K12E 
variant (with a charge of +4) was produced but did not exhibit activity, whereas in this 
study the nisin-AAA K12E variant (with a charge of +3) was not able to self-induce but 
was active once induced13. Changing  the amino acid sequence of nisin A at the hinge 
region (from NMK to AAA) lowers the overall charge of the peptide, and thus could have 
an effect on the peptide’s ability to induce and its bioactivity (i.e. the combined impact 
on production and activity). However, the nisin A K12E variant was not subjected to 
induction with Nisaplin, therefore the peptide may have been active but not produced at 
a high concentration. The introduction of the positively charged amino acids, K or R, at 
position H31 resulted in the retention of the self-induction property. It is relevant that 
sustained self-induction was exclusive only to the three natural positively charged amino 
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acids at position H31 (and N which is uncharged), suggesting that the positively charged 
amino acids at position H31 are important for maintaining self-induction. Previous studies 
investigating the effects of amino acid substitutions on the bioactivity and/or production 
of nisin have shown varying results13,19. By and large, substituting with a negatively 
charged amino acid has a detrimental effect on bioactivity/production, as in the cases of 
nisin Z hinge mutants N20E, M21E and K22E, nisin A mutants N20D and K22D, and 
nisin A mutant K12D13,18–20. However, one instance where negatively charged 
substitutions have had a beneficial effect with respect to specific activity relates to the 
derivatives S29D and S29E, which exhibited a two-fold decrease in MIC against 
lactococci21. Positively charged amino acid replacements have had a varied impact on the 
bioactivity/induction properties of nisin. For example, several studies have demonstrated 
the enhanced activity of variants with positively charged residues, most notably the nisin 
Z mutants N20K and M12K which displayed enhanced bioactivity against several Gram-
negative bacteria21,22. Replacement of A 20 (N20) with R (N20R) resulted in reduced 
bioactivity against several targets, including staphylococci and streptococci18. Other 
evidence indicates that positively charged amino acids may not play a huge role in the 
induction activity of nisin, as shown in a previous study whereby the replacement of 
positively charged amino acids, K12 and H31, with an A residue demonstrated similar 
induction abilities than original nisin A3. However, our data substantiates the detrimental 
impact of introducing the negatively charged amino acids D and E at position K12 of the 
nisin-AAA variant, along with the potential importance of having a positively charged 
residue at position H31, with regards to induction. The importance of a positively charged 
amino acid at position K12, with regards to induction, in the nisin-AAA variant in 
comparison to the lack of importance in original nisin A may be due to the overall net 
charge of both peptides. Nisin-AAA is by nature a less positively charged peptide due to 
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replacing the positively charged K amino acid at position 22 with an A. The replacement 
of a second positively charged amino acid at position 12, decreasing the overall charge 
yet again, may be responsible for its loss of induction, in contrast to original nisin A 
retaining induction. 
 In addition to positions N20, M21 and K22, K12 and H31 have previously been 
shown to be trypsin and chymotrypsin cut sites, and altering these two positions results 
in resistance to cleavage by these enzymes11. From the deferred antagonism results, 
(Figure 2.4) several variants would potentially allow the peptide to retain its self-
induction properties K12V, K12Q, K12W, K12T, K12A, K12C, H31N, H31K and H31R. 
Of these alternatives K, R and N are known to be targeted by trypsin, and the peptide 
bonds formed by aromatic residues Y, W and F (not naturally found in nisin) are cleaved 
by chymotrypsin21,22. In a previous study a variant with a Q substitution at position H31 
was also shown to be susceptible to chymotrypsin11. Consequently, with just four possible 
advantageous substitutions remaining at position K12 (V, A, T and C), with regards to i) 
maintaining bioactivity, ii) acquiring trypsin and chymotrypsin resistance, and iii) 
sustaining self-induction, and none at position H31, it may be construed that a nisin-AAA 
variant acquiring each of these three attributes is not feasible. Added to this issue is the 
production of two variants, one modified (Dhb) and one unmodified, where T is present 
at position K12, both requiring separation and purification of each derivative for further 
analysis. 
The deferred antagonism assay results indicate that all nisin-AAA variants, except 
K12D, could be produced following induction with wild type nisin. The ability of each 
nisin-AAA variant producer to sustain production through a self-induction loop was 
investigated by first “kick starting” the production of nisin with a minimal amount of 
Nisaplin and subsequently passaging the sample into fresh media, thus diluting the 
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concentration of Nisaplin present. Several variants failed to retain its auto-induction 
ability once the concentration of Nisaplin began to decrease (K12G, K12E, H31W, H31G, 
H31E, H31T, H31D, H31P, H21C and H31F), verifying that these variants lack the ability 
to induce in the absence of nisin peptide (Figure 2.5). Some variants exited the induction 
loop after a prolonged period. These variants were capable of signal production at a 
Nisaplin concentration of 0.0025g/ml, however the signal appeared to be lost when the 
Nisaplin concentration fell to 0.0025ng/ml (K12N, K12H, K12P, K12F, H31V, H31Q, 
H31S, H21M, H31I, H31A, H21L and H31Y). The initial signalling but subsequent loss 
implies that these variants have some ability to signal induction, but either require a higher 
concentration or are unable to fully enable the induction loop. Along with variants that 
could initially self-induce without the aid of Nisaplin, there were six other variants that, 
once “kick started”, could maintain the induction loop after Nisaplin concentrations were 
depleted (K12M, K12I, K12L, K12Y, K12R and K12S). All of these variants are K12 
substitutions, suggesting that the H31 position is less amenable to change with regards to 
induction, with only four amino acid variations at H31 facilitating self-induction in 
comparison to thirteen at position K12 (Figure 2.5). Other than all variants being either 
neutral or positively charged, there appears to be no other obvious pattern (including size, 
polarity, position (surface or buried), aromatic, aliphatic, cyclic and acyclic) connecting 
these variants.  
GFP expression was monitored during growth of the L. lactis NZ9000 pNZ8150-
gfp+ producer strain, using each nisin-AAA K12 and H31 variant as an inducer which 
enabled us to examine the induction properties of the derivatives over a 24hr period. This 
analysis revealed that the same six variants capable of maintaining a self-induction loop 
once “kick started” (Figure 2.5) along with the original variants capable of self-induction 
(Figure 2.4), were able to induce a self-induction loop, detected by increased levels of 
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GFP (Figure 2.6). Interestingly, eight variants that could not maintain or initiate a self-
induction loop in the previous assay (Figure 2.5), could “kick start” an auto-induction 
loop, again detected by increased levels of GFP (K12H, H31Q, H31L, H31A, H31I, 
H31M, H31T and H31P) (Figure 2.6). 
Previous work has indicated that the variant K12V-AAA-H31V holds promise as 
a potential therapeutic, in that it is trypsin and chymotrypsin resistant whilst retaining 
much of its specific activity, and thus this variant became the focus of further 
investigation in this study11. It was observed that the K12V-AAA-H31V variant had to 
be used at a much higher concentration than that of original nisin A to induce GFP 
production (Figure 2.7), with nisin A initiating an induction response at 5ng/ml and 
K12V-AAA-H31V only producing a similar response at 100ng/ml25. However, a nisin A 
concentration as high as 100ng/ml appears to stress the cells, shown by the lag in growth, 
but does not in the case of the K12V-AAA-H31V mutant (Figure 2.7 C). The need to add 
more mutant peptide (~100ng/ml) to initiate induction, along with the lack of a lag in 
growth of the mutant peptide in comparison the original nisin A control, corroborates the 
finding that the mutant peptide is slightly less active (two-fold increase in MIC) than the 
original nisin A (Figures 2.7). 
 We show that substituting K for a V at position K12 has no detrimental effect on 
the K12V-AAA-H31V peptide’s induction ability (Figures 2.4 A, 2.5 A and 2.6 A). 
However, substituting H for a V, or indeed any natural amino acid, at position H31 leads 
to a loss of the ability to initiate the induction loop (Figures 2.4 B, 2.5 B and 2.6 B). The 
amino acid substitutions H, R, N and K at position H31 are the only substitutions capable 
of maintaining the self-induction loop, and so we infer that nisin-AAA variants with a V 
at position K12 and either R, N or K at position H31 may be the best possible 
configuration for nisin-AAA to preserve both bioactivity and self-induction. However, 
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given the fact that N, K and R are known to be trypsin or chymotrypsin cut sites, we 
would predict that any substitution that is made at position H31 will result in either the 
loss of induction or result in the digestion by trypsin or chymotrypsin. Future work would 
require generating these variants (K12V-AAA-H31R, K12V-AAA-H31N and K12V-
AAA-H31K) and testing each for self-induction, trypsin and chymotrypsin resistance, 
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Oligonucleotide  Sequence  
pCI372FOR 5’-cgggaagctagagtaagtag-3’ 
pCI372REV 5’-acctctcggttatgagttag-3’ 
NisK12degFOR  5’-pho- ccc ggt tgt nnk aca gga gct ctg atg ggt tgt gct gcg gct aca -3’  
NisK12degREV  5’-tgt agc cgc agc aca acc cat cag agc tcc tgt mnn aca acc ggg -3’  
NisH31degFOR  5’-pho- tgt agt att nnk gta agc aaa taa tct aga gtc gac ctg-3’  
NisH31degREV  5’ ttt gct tac mnn aat act aca atg aca agt tgc tgt -3’  
K12MFor  5'- ccc ggt tgt atg aca gga gct ctg atg ggt tgt gct gcg -3’  
K12MRev  5'- agc tcc tgt cat aca acc ggg tgt aca tag cga aat act -3’  
K12DFor 5'- ccc ggt tgt gac aca gga gct ctg atg ggt tgt gct gcg -3’ 
K12DRev 5'- agc tcc tgt gtc aca acc ggg tgt aca tag cga aat act -3’   
H31FFor  5'- tgt agt att ttt gta agc aaa taa tct aga gtc gac ctg -3’  
H31FRev  5'- ttt gct tac aaa aat act aca atg aca agt tgc tgt agc -3’  
H31PFor  5'- tgt agt att ccc gta agc aaa taa tct aga gtc gac ctg -3’  
H31PRev  5'- ttt gct tac ggg aat act aca atg aca agt tgc tgt agc -3’  
Table 2.2 Pho -5’- Phosphate modification, bold – location for site-saturation 
















H31H  3193 3195 H31C 3159 3159 





H31N  3170 3170 H31D 3171 3175 
H31K  3184 3184 H31R 3212 3212 
H31Q  3184 3183 H31Y 3219 3219 
H31W  3242 3241 H31L 3169 3169 






H31I 3169 3169 
H31M  3187 3188 H31P 3153 3153 
H31E  3185 3185 H31F 3203 3203 
Table 2.3 Molecular masses of nisin-AAA variants at position H31. *Indicates 
dehydrated forms (hydrophobic modified residues), i.e. Dhb in the case of T (H31T) and 























K12H  3202 3202 K12C 3168 3193 





K12N  3179 3179 K12D 3180 - 
K12K  3193 3193 K12R 3221 3221 
K12Q  3193 3193 K12Y 3228 3227 
K12W  3251 3251 K12L 3178 3178 






K12I 3178 3177 
K12M  3196 3196 K12P 3162 3162 
K12E  3194 3194 K12F 3212 3211 
Table 2.4 Molecular masses of nisin-AAA variants at position K12. * Indicates 
dehydrated forms (hydrophobic modified residues), i.e. Dhb in the case of T (K12T) and 
Dha in the case of S (K12S). 
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Variant  Sequence  
H31H  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
H31A  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattgcggtaagcaaa  
H31C  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtatttgtgtaagcaaa  
H31D  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattgatgtaagcaaa  
H31E  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattgaggtaagcaaa  
H31F  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtatttttgtaagcaaa  
H31G  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattggggtaagcaaa  
H31I  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattattgtaagcaaa  
H31K  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattaaggtaagcaaa  
H31L  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattttggtaagcaaa  
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H31M  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattatggtaagcaaa  
H31N  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattaatgtaagcaaa  
H31P  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcccgtaagcaaa  
H31Q  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcaggtaagcaaa  
H31R  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcgggtaagcaaa  
H31S  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtatttcggtaagcaaa  
H31T  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattactgtaagcaaa  
H31V  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattgtggtaagcaaa  
H31W  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtatttgggtaagcaaa  
H31Y  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtatttatgtaagcaaa  
                 Table 2.5 Full sequence of nisin-AAA including mutations at position H31. Underlined – location of mutation site.
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Variant  Sequence  
K12K  attacaagtatttcgctatgtacacccggttgtaaaacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
K12A  attacaagtatttcgctatgtacacccggttgtgctacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
K12C  attacaagtatttcgctatgtacacccggttgttgtacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
K12D  attacaagtatttcgctatgtacacccggttgtgatacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
K12E  attacaagtatttcgctatgtacacccggttgtgagacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
K12F  attacaagtatttcgctatgtacacccggttgttttacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
K12G  attacaagtatttcgctatgtacacccggttgtgggacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
K12H  attacaagtatttcgctatgtacacccggttgtcatacaggagctctgatgggttgtgctgcggctacagcaactngtcattgtagtattcacgtaagcaaa  
K12I  attacaagtatttcgctatgtacacccggttgtattacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
 106 
K12L  attacaagtatttcgctatgtacacccggttgtctgacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
K12M  attacaagtatttcgctatgtacacccggttgtatgacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
K12N  attacaagtatttcgctatgtacacccggttgtaatacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
K12P  attacaagtatttcgctatgtacacccggttgtcctacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
K12Q  attacaagtatttcgctatgtacacccggttgtcagacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
K12R  attacaagtatttcgctatgtacacccggttgtcgtacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
K12S  attacaagtatttcgctatgtacacccggttgtagtacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
K12T  attacaagtatttcgctatgtacacccggttgtacgacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
K12W  attacaagtatttcgctatgtacacccggttgttggacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
K12Y  attacaagtatttcgctatgtacacccggttgttatacaggagctctgatgggttgtgctgcggctacagcaactngtcattgtagtattcacgtaagcaaa  
K12V  attacaagtatttcgctatgtacacccggttgtgttacaggagctctgatgggttgtgctgcggctacagcaacttgtcattgtagtattcacgtaagcaaa  
                 Table 2.6 Full sequence of nisin-AAA including mutations at position K12. Underlined – location of mutation site.
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Figure 2.3 Deferred antagonism assay results showing zones of inhibition of nisin K12X-
AAA and AAA-H31X variants against L. lactis HP. (A), (B), (C) and (D) depict 
uninduced variants K12W, K12E, H31Y and H31S respectively, plated on agar without 
Nisaplin. (E), (F), (G) and (H) depict induced variants K12W, K12E, H31Y and H31S 
respectively, plated on agar supplemented with 1µg/ml of Nisaplin (Danisco). Nisaplin 





K12X Full bank: Nisin K12X-AAA Activity against L. lactis HP*


























H31X Full bank: Nisin-AAA-H31X Activity against L. lactis HP*

























Figure 2.4 Deferred antagonism results of (A) nisin K12X-AAA and (B) nisin AAA-
H31X variants supernatant against L. lactis HP. Results are expressed as the diameter 
(mm) of inhibitory zone minus the diameter of spot.   
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Well assay: Nisin K12X-AAA variants vs. L. lactis HP
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Well assay: Nisin AAA-H31X variants vs. HP
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Figure 2.5 Well assay results of (A) K12X and (B) H31X variants against L. Lactis HP. 
Results are expressed as the diameter (mm) of inhibitory zone minus the diameter of well. 
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Figure 2.6 Results of nisin-A GFP induction using (A) K12X and (B) H31X variants. 
Green bars indicate naturally self-inducing variants; red bars indicate variants incapable 
of self-induction but capable of retaining induction when induced at 0.0025ng/ml 
Nisaplin (first passage); blue bars indicate variants incapable of self-induction but capable 
of retaining induction at 0.0025µg/ml Nisaplin (second passage); grey bars indicate 
variants incapable of self-induction but capable of retaining activity when induced with 
2.5µg/ml Nisaplin; and patterned bars indicate positively charged amino acid changes.   
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A      B 
Growth curve of GFP L. lactis  strain: Induced by 10ng/ml Nisin
















RLU emitted by GFP L. lactis  strain: Induced by 10ng/ml Nisin variants













Growth curve of GFP L. lactis  strain: Induced by 100ng/ml Nisin
















RLU emitted by GFP L. lactis  strain: Induced by 100ng/ml Nisin variants







































Figure 2.7 In vitro results of growth curves and nisin-A GFP expression, uninduced and 
induced with both nisin A and nisin K12V-AAA-H31V separately, using 10 ng/ml and 
100 ng/ml concentrations. (A) and (C) represent absorbance growth curves whereas (B) 
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Conserving and restoring the use of antibiotics with the aid of bacteriocins. 
 





The threat of antibiotic resistance has become a global concern, with many 
clinically significant pathogens now showing increased resistance to multiple antibiotics. 
The search for alternative therapeutics has led to the analysis of possible solutions such 
as the use of bacteriocins. Bacteriocins typically have high potency, low toxicity and can 
be easily bioengineered making them ideal candidates. In this study 11 bacteriocins were 
tested for antimicrobial activity against five clinically significant bacteria. Nisin Z and 
lacticin 3147, which demonstrated the most promising results, were selected for 
combination studies using three different antibiotics (penicillin G, vancomycin and 
methicillin) in vitro and ex vivo. Results suggest that bacteriocins such as nisin Z and 
lacticin 3147 may aid in prolonging the use of certain antibiotics which are under threat 
of becoming ineffective due to antibiotic resistance, and can be used in combination with 





Bacteriocins are bacterially produced, ribosomally synthesized, often post-
translationally modified antimicrobial peptides, having either a broad or narrow spectrum 
of antimicrobial activity1. Their activity against numerous clinically significant 
pathogens, including various strains of methicillin resistant Staphylococcus aureus 
(MRSA), Staphylococcus epidermidis, Salmonella enterica and Clostridium difficile, has 
heightened interest in their potential as therapeutics1–7. This is particularly relevant in an 
age of multi-drug resistant (MDR) bacteria combined with decreased efficacy of 
traditional antibiotics2. In recent years the growing issue of antibiotic resistance along 
with the disturbance of the human commensal microbiota through the administration of 
antibiotics has led researchers to investigate alternative therapies8–10. Other notable 
attributes of bacteriocins are their activity at relatively low concentrations, low toxicity 
and the possibility of in situ production by probiotics2. Studies examining the potiential 
use of bacteriocin producing probiotic bacteria, rather than purified bacteriocins, may also 
aid in making the use of bacteriocins more cost-effective.11 
Nisin Z and Lacticin 3147 are both broad spectrum lantibiotics (class I 
bacteriocins) and are produced by Lactococcus lactis. Nisin has been used within the food 
industry as a food preservative since 1953 and has been approved by the EU, WHO and 
USFDA, making it an ideal candidate for further research as a potential therapeutic. 
Lacticin 3147 is comprised of two peptides, α and β, and demonstrates potent activity 
against a wide range of Gram-positive pathogens. Nisin and Lacticin 3147 have both 
exhibited in vitro activity against various clinically significant skin pathogens including 
MRSA, Cutibacterium acnes (previously referred to as Propionibacterium acnes), 
Streptococcus pyogenes and Corynebacterium species12–16. They have also previously 
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been shown to work synergistically with various other antibiotics against Gram-negative 
bacteria, such as polymyxin, amikacin and colistin17–19. 
Antibiotic resistance has become a global problem, so much so that governing 
bodies have started to take action. In 2015 the WHO (World Health Organisation) issued 
a “global action plan on antimicrobial resistance”. After the “United Nations general 
assembly” in 2016 all member of states were required to implement their own national 
action plan for combating antibiotic-resistant bacteria by 2017. In 2015 the United States 
Federal Government put in place the “national action plan for combating antibiotic-
resistant bacteria” and in 2017 the EU Commission began implementing the “EU one 
health action plan against AMR” which has been developed since 201120. Both reports 
have commonalities pertaining to the importance of slowing the emergence of resistance 
bacteria, preventing the spread of resistant infections, accelerating basic and applied 
research, innovation and development for new antibiotics, other therapies and 
vaccines21,22. This study addresses these goals by investigating the potential for 
conserving the amount of antibiotic needed for the treatment of skin pathogens, 
developing new therapeutic strategies and restoring ones with now ineffective 
antimicrobial activity. 
Cutibacterium acnes (C. acnes), previously classed as Corynebacterium parvum 
and more recently Propionibacterium acnes, is a Gram-positive, aerotolerant, commensal 
human skin bacterium capable of producing biofilms that contributes to the development 
of acne23. Acne affects 80% to 90% of the population at some stage in their life and is the 
primary reason for dermatologist visits24,25. Recent studies report the increasing 
emergence of C. acnes resistance to various antibiotics, including fluoroquinolones, 
macrolides, erythromycin, clindamycin, tetracycline and trimethoprim-
sulfamethoxazole26–28. To date C. acnes remains susceptible to -lactam antibiotics, 
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including penicillin. However, the possibility of acquiring resistance either through the 
alteration of the PBP (Penicillin binding protein) or gene transfer remains a cause for 
concern; strains have already been identified containing the -lactam gene, which is not 
normally associated with Gram-positive bacteria29. Continual treatment with antibiotics 
such as penicillin, also increases the risk of other skin species developing resistance, for 
example the cutaneous staphylococcal flora of acne patients30. 
Corynebacterium xerosis (C. xerosis) is a commensal bacteria found on human 
skin and mucous membranes and rarely causes infections of any clinical relevance, 
however there have been reports of the bacteria contributing to strong underarm odours31–
33. Previous studies have indicated that underarm odour was solely produced by aerobic 
coryneforms, the majority of which were identified as C. xerosis. In the same study 34 
males were screened for underarm odour producing bacteria and 33 were positive for 
coryneforms, with population density strongly associated with the intensity of the 
odour34. Enterococcus faecium is another example of a bacterium that did not gain much 
attention until the mid to late 1990s when antibiotic resistant E. faecium nosocomial 
infections began to emerge with growing frequency, including aminoglycosides, 
ampicillin and vancomycin resistant Enterococcus (VRE) strains35,36. Enterococci can 
also be intrinsically resistant to a variety of antibiotics such as clindamycin, penicillin and 
cephalosporins, making their treatment more difficult.  
While nosocomial and community acquired infections have always been cause for 
concern, the excessive and improper use of antibiotics has led to certain pathogens 
becoming increasingly difficult to manage37. MRSA is a Gram-positive coccus and has 
become one of the most worrying pathogens to date due to its highly mutable nature. In 
the 1940s S. aureus infections were originally treated with penicillin and later (1960s) 
penicillin-related antibiotics such as methicillin and oxacillin; however, new forms of the 
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pathogen resistant to β-lactam antibiotics (including penicillins, cephalosporins and 
carbapenams) began to emerge shortly thereafter38–40. Reports have shown more recent 
cases of resistance to other antibiotics such as erythromycin, fluoroquinolones, 
tetracycline and clydamicin41–43. Vancomycin is now the drug of choice to treat an MRSA 
infection, but a decreased susceptibility to this drug is also on the rise (known as 
vancomycin resistant Staphylococcus aureus (VRSA), with an Minimum Inhibitory 
Concentration (MIC) value of ≥32μg/ml rendering it completely resistant43. 
Staphylococcus aureus is ubiquitous in nature with approximately 20-30% of individuals 
displaying nasal passage colonisation persistently and 60% intermediately37,44,45. It causes 
a multitude of skin diseases ranging from superficial infections such as pimples, boils and 
impetigo to deeper skin infections such as abscesses and cellulitis. MRSA is also 
frequently associated with wound infections, including surgical site infections, and upon 
entering the bloodstream through cuts or lesions can lead to internal infections46–48. 
The threat of pandrug-resistance (resistance to all current drugs) is of growing 
concern for bacteria such as MRSA with 95% of strains not responding to first line 
antibiotics and increasing numbers of studies reporting resistance to alternatives such as 
vancomycin49. This study attempts to address this now global problem by using 
bacteriocins in combination with both currently used and now ineffective antibiotics in 
an effort to reduce toxicity and antibiotic resistance development, and to restore activity 
to antibiotics which have lost their efficacy.  
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2.3 Experimental procedures 
 
2.3.1 Bacterial strains and growth conditions 
All bacteriocin producing strains and pathogen strains are listed in tables 3.1 and 3.2 
and were obtained from the UCC culture collection. L. lactis strains were grown in GM17 broth 
or agar (1.5% agar) (Oxoid) supplemented with 0.5% glucose and incubated at 30°C (Table 
3.1). All Streptococcus uberis (S. uberis), Streptococcus salivarius (S. salivarius), S. aureus, 
E. faecium and C. xerosis strains were grown in BHI broth or agar (1.5% agar) and incubated 
at 37°C (Tables 3.1, 3.2). C. xerosis DPC 5629 was supplemented with tween80 0.5% v/v. C. 
acnes LMG 16711 was grown in Reinforced Clostridium Media (RCM) (Oxoid) and incubated 






















L. lactis  MG1363 
pMRCO1 
pOMO2 
Lacticin 3147 GM17 30°C aerobic (50) 
L. lactis 
DPC5552 
Lacticin 481 GM17 30°C aerobic (51) 
L. lactis 
(NZ9700) 
Nisin A GM17 30°C aerobic (52) 
L. lactis NZ9800 
pCI372nisF 
Nisin F GM17 30°C aerobic (53) 
L. lactis NZ9800 
pCI372nisQ 
Nisin Q GM17 30°C aerobic (53) 
L. lactis NZ9800 
pCI372nisZ 
Nisin Z GM17 30°C aerobic (53) 
S. uberis 42 Nisin U BHI 37°C aerobic (
54) 
S. uberis D536 Nisin U2 BHI 37°C aerobic (
53,54) 
S. aureus C55 
Staphylococcin 
C55 
BHI 37°C aerobic (55) 
S. aureus TY4 
Staphylococcin 
TY4 
BHI 37°C aerobic (56) 
S. salivarius 
DPC6490 
Salivaricin A5 BHI 37°C anaerobic (57) 
Table 3.1 Bacteriocin producer strains and growth media used in this study. Brain Heart 
Infusion (BHI) (Oxoid) (1.5% agar) and GM17 (Oxoid) supplemented with 0.5% glucose 




Bacterial strain Media Incubation temp. Aerobic/anaerobic 
C. acnes LMG16711 RCM 37°C anaerobic 
C. xerosis DPC5629 BHI 37°C * aerobic 
E. faecium UCC1 BHI 37°C aerobic 
E. faecium UCC2 BHI 37°C aerobic 
MRSA ST291 BHI 37°C aerobic 
Table 3.2 Skin and gut relevant pathogens used in this study. Brain Heart infusion (BHI, 
Oxoid), Reinforced Clostridium Media (RCM, Oxoid). *Supplemented with tween80 0.5% 
v/v. All bacterial strains were obtained from the UCC culture collection. 
 
2.3.2 Deferred antagonism 
Following overnight incubation, the bacteriocin producer strain (Table 3.1) was spotted 
onto appropriate agar-containing media (Table 3.1) and incubated for 18hrs. Following 
incubation the producer strain splates were UV treated for 30mins. Indicator strains (C. acnes 
LMG 16711, C. xerosis DPC 5629, E. faecium UCC1, E. faecium UCC2 and MRSA ST291) 
were grown to stationary phase and 50µl was subsequently inoculated into 50ml of appropriate 
media (0.75% agar). This was then overlaid onto the bacteriocin producer strains plates. The 
overlaid plates were incubated overnight at the appropriate temperature and aerobic/anaerobic 
conditions for the indicator strains (Table 3.2). The results were represented as the diameter of 
the zone of inhibition minus the diameter of the bacteriocin producer spot and were measured 
using digital callipers (Figure 3.1). 
 
2.3.3 Purification of Lacticin 3147 
Following overnight incubation 10mls of L. lactis MG1363 (Lacticin 3147 pMRCO1 
pOMO2) producing strain was added to 3 litres of Tryptone Yeast (TY) broth. 20X Glucose 
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(5%) and 20X β-glycerophosphate (5%) were also added and together incubated at 30°C for 
16 hrs. The culture was subsequently centrifuged for 15 mins at 7000g. The pelleted cells were 
re-suspended in 300ml of 70% isopropanol (IPA) containing 0.1% v/v trifluoroacetic acid 
(TFA) and stirred at 4°C for 4 hrs before centrifugation at 7000 rpm for 15 mins. The volume 
of the supernatant was subsequently reduced by 70% using rotary evaporation (Buchi) (40˚C 
at 50mbar), in order to remove the IPA giving a final volume of ~ 60ml. The concentrated 
supernatant was subjected to solid-phase extraction (SPE) using a 10g/60ml Strata C-18E Giga-
Tube (Phenomenex) post equilibration with 60ml methanol followed by 60ml H2O. The 
column was subsequently washed with 120ml 30% ethanol and the peptide was eluted from 
the column with 60ml 70% IPA (pH 2).  
For Reverse-Phase High Performance Liquid Chromatography (RP-HPLC), 10ml 
aliquots were concentrated through rotary-evaporation to ~2ml. Injection volumes of 1800µl 
were applied to a Phenomenex C12 Reverse-Phase (RP) HPLC column (Jupiter 4µ 90Å, 250 X 
10.0mm, 4µm) previously equilibrated with 25% IPA containing 0.1% trifluoroacetic acid 
(TFA). The column was set up in a gradient of 30% IPA containing 0.1% TFA to 60% IPA 
containing 0.1% TFA in 4 to 40 mins at a flow rate of 1.2ml/min (Shimazdu, USA FMG Inc.). 
Fractions that generated a peak were pooled seperately and rotary-evaporated to remove 
approximately 40% of the IPA solvent before freeze-drying. 
 
2.3.4 Minimum Inhibitory Concentration (MIC) assays 
MIC assays were carried out in triplicate on Nisin Z and Lacticin 3147 using target 
strains C. xerosis DPC 5629, C. acnes LMG 16711, E. faecium UCC1, E. faecium UCC2 and 
MRSA ST291. 96 well microtitre plates (Sarstedt) were initially treated with bovine serum 
albumin (BSA) by adding 200µl of a 1% BSA and 5% PBS in sterile deionised water solution 
to each well, incubating at 37°C for 30 mins before decanting and washing with a 5% PBS in 
 136 
water solution. Peptides and antibiotics were adjusted to a 5µM (16.67g/ml nisin Z, 
30.75g/ml lacticin 3147, 1.78g/ml penicillin G, and 7.245g/ml vancomycin) starting 
concentration and a 2-fold serial dilution was performed on each peptide. The target strains 
were subcultured from an overnight (Table 3.2) and incubated until they reached an OD600 of 
0.5nm. The strains were diluted in appropriate liquid media (Table 3.2) to a final concentration 
of 105 cfu/ml and 200µl was added to each well. The plate was incubated for 18hrs (Table 3.2) 
followed by MIC determination. 
 
2.3.5 Growth Curve assays  
Following overnight incubation, bacterial strains (Table 3.2) were transferred into 
appropriate liquid media (Table 3.2). Upon reaching an OD600 reading of 0.5nm, the cultures 
were supplemented with purified peptide (nisin Z/lacticin3147) and antibiotic (penicillin G/ 
vancomycin) (concentrations outlined in Figure 3.2), and 0.2ml was subsequently transferred 
to a 96 well microtitre plate (Sarstedt) in triplicate. Growth curves were measured 
spectrophotometrically, using a SpectraMax MP3 spectrophotometer and were plotted with 
incubation time as the abscissa and absorbance as the vertical axis. 
 
2.3.6 Time-kill assays 
Following overnight incubation, cultures were transferred into respective liquid media. 
Upon reaching an OD600 reading of 0.5nm, 20µl was transferred into 1 ml of appropriate broth 
(Table 3.2) containing purified peptide (nisin Z/ Lacticin 3147) alone and in combination with 
antibiotic (penicillin G/ vancomycin/ methicillin) (concentrations outlined in Figures 3.3, 3.4). 
The samples were incubated for 1 and 3 hrs, and/or 3, 6, 9, 12 and 24hrs at applicable 
temperatures (Table 3.2). Cell growth was measured by performing a 10-fold serial dilution of 
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cultures in one-quarter-strength Ringer solution and plating and enumerating viable cell counts 
on appropriate agar plates (Table 3.2)58. 
 
2.3.7 FIC/checkerboard assays 
For FIC (Fractional Inhibitory Concentration) experiments, eight times the MIC of two 
antimicrobials (nisin Z and methicillin) were transferred separately into two 96 well microtitre 
plates upon which a serial dilution was then performed horizontally across each plate in broth 
(50µl). 50µl from plate 1 was added vertically to plate 2. The overnight culture (MRSA 
ST291), having been transferred into BHI media and grown until it reached an OD600 reading 
of 0.5nm, was diluted to a final concentration of 105 cfu/ml-1 and added to each well17. 
 
The FIC is characterised by the following equation: 
FIC = FICX + FICY = (X/MICX) + (Y/MICY) 
Where “X” is the minimum amount of antimicrobial X used in combination with another that 
achieved an inhibitory effect and the MICX is the MIC of the same antimicrobial that produces 
an inhibitory effect on its own. FIC index results are as follows: FIC ≤ 0.5 is synergy, 0.5 < 
FIC ≤ 0.75 is partial synergy, 0.75 < FIC ≤ 1.0 is additive, FIC > 1.0 is indifferent and FIC > 
4 is antagonistic17,59. 
 
2.3.8 Ex-vivo porcine skin model 
Approximately 2cm by 2cm squares of pig skin samples were cut with a scalpel and 
stored at -20C. Samples were sterilised by soaking in 80%  Propan-2-ol for 10mins before 
washing with deionised sterile water and subsequently exposing to UV light for 15mins. 
Samples were inoculated with OD600 0.5nm (approximately 107cfu/ml) MRSA ST291 and 
incubated at 37°C for 1hr. 50l of either 800g/ml nisin and/or 32g/ml methicillin was 
 138 
pipetted onto the skin and spread over the surface using an inoculating loop before incubating 
at 37C for 3hrs. Enumeration was carried out by homogenizing the skin in a stomacher 
(Masticator basic, IUL) with 10mls PBS for 15secs and performing plate counts on MRS agar 




An initial screening using deferred antagonism agar diffusion assays was performed to 
determine if selected bacteriocins (Table 3.1) displayed antimicrobial activity against five 
pathogens (Figure 3.1). Each bacteriocin tested (Table 3.1) produced an antimicrobial effect 
against at least one of the five pathogens, thus suggesting possible bacteriocin production along 
with specific activity. Nisin Z and lacticin 3147 displayed zones of clearing greater in size, 
against four of the pathogens, than the majority of bacteriocins being considered, and were 
therefore selected for further investigation. It should also be noted that no bacteriocin producer 
produced a zone of clearing against the strain MRSA ST291.  
In order to assess specific activity, high performance liquid chromatography (HPLC) 
and freeze-drying was carried to generate purified peptide before using the peptide in broth 
based 96 well microtitre plate assays to determine MICs against the same five indicator strains 
(Table 3.2). The MIC was visually determined as the lowest concentration of peptide that 
resulted in the absence of growth of the target strain after 18hrs of incubation at 37C. It was 
apparent that for C. acnes LMG 16711, both antibiotics, penicillin G and vancomycin, had a 
greater antimicrobial effect than either bacteriocin (nisin Z or lacticin 3147) with nisin Z being 
the more effective of the two having an MIC difference of 0.625g/ml when compared to 
vancomycin (Table 3.3). In the case of both E. faecium strains both nisin Z and lacticin 3147 
produced a greater antimicrobial effect than either antibiotic with lacticin 3147 giving the 
lowest MIC values of 0.12g/ml and 0.48g/ml (Table 3.3). Lacticin 3147 again produced the 
lowest MIC value against C. xerosis DPC 5629 and had a lower MIC value than both nisin Z 
and penicillin G when tested against MRSA ST291. However, vancomycin remains the most 
effective antimicrobial for MRSA ST291 that was tested in this study (Table 3.3).  
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From the MIC results, lacticin 3147 was selected for further analysis by combination 
growth curve and time-kill assays with penicillin G and vancomycin against the strains C. 
acnes LMG 16711, E. faecium UCC1, E. faecium UCC2, C. xerosis DPC 5629and MRSA 
ST291 (Figures 3.2, 3.3). In each instance, when the peptide and antibiotic were used singly at 
sub-lethal concentrations, there was an increase of lag time and/or lack of full growth potential. 
However, when lacticin 3147 and an antibiotic (penicillin G or vancomycin) were used in 
combination, compared to either compound used alone, growth appeared to be completely 
inhibited. This was true for all five strains tested. In order to examine the antimicrobial effects 
of lacticin 3147 in combination with either penicillin G or vancomycin over a defined time 
period, each test strain (Table 3.2) was exposed to different concentrations of lacticin 3147 and 
antibiotic (penicillin G or vancomycin) in an appropriate broth for a period of 1 or 3hrs at 37C 
(Figure 3.3).  In the case of all five test strains, when lacticin 3147 was used in combination 
with antibiotic, cell numbers decreased to a greater extent to when they were used alone. In the 
case of both C. acnes LMG 16711 and C. xerosis DPC5629 after 3hrs of treatment, cell 
numbers remained static or slightly decreased (in comparison to untreated control) when 
treated with 0.176g/ml penicillin G (C. acnes LMG 16711) or 0.905g/ml vancomycin (C. 
xerosis DPC 5629) and decreased by 2-log when treated with 7.5g/ml (C. acnes LMG 16711) 
or 1.2g/ml (C. xerosis DPC 5629) Lacticin 3147. However cell numbers decreased by >5-log 
when treated in combination with either penicillin G (C. acnes LMG 16711) or vancomycin 
(C. xerosis DPC 5629) (Figures 3.3 A, 3.3 C). After 3hrs E. faecium UCC2 cell counts also 
decreased significantly (>8-log) when lacticin 3147 and penicillin G were used in combination, 
in comparison to only decreasing by a maximum of 5-log when treated with either alone. For 
E. faecium UCC1 at a 3hr time point there was less of a decrease in cfu/ml when lacticin 3147 
and vancomycin were used in combination in comparison to when used alone, which is 
consistent with results from growth curves (Figure 3.2). At a time point of 3hrs MRSA ST291 
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displayed a decrease of 2-log when treated with vancomycin alone, and 5-log when treated 
with lacticin 3147 alone, in comparison to a 6-log when in combination.  
In a further attempt to demonstrate the use of bacteriocins for the enhancement of 
antibiotic efficacy, FIC assays were implemented in order to determine whether a bacteriocin 
can work synergistically with an antibiotic against a bacteria that is known to be resistant to 
the same antibiotic. In this case nisin Z was chosen because it has already been approved by 
the FDA, making it a potentially more easily and rapidly implemented therapeutic. The MIC 
of >64g/ml for methicillin confirms that the S. aureus strain used is indeed an MRSA. The 
FIC assays confirmed that a combination of vancomycin and nisin Z had only an additive effect 
on MRSA ST291 (FIC 1.01), while a combination of methicillin and nisin Z gave a more 
promising result of having a partially synergistic effect (FIC 0.75) (Table 3.3). 
Further time-kill assays were carried out to establish the effect of nisin Z and methicillin 
alone or in combination on MRSA ST291 over 3, 6, 9, 12 and 24hr periods (Figure 3.4 A). It 
was ascertained that over a 24hr period nisin Z at a concentration of 1g/ml and methicillin at 
a concentration of 32g/ml did not have significant inhibitory effects on the growth of MRSA 
ST291, but when used in combination gave a 5-log cfu/ml reduction. At the 3hr time point 
nisin Z and methicillin alone had a maximum of a 2-log difference. However, over the other 
time points (6, 9, 12 and 24hrs) it can be seen that both nisin Z and methicillin alone could not 
maintain this effect and there is little to no difference in cfu/ml at the 24hr time point. This is 
in contrast to when nisin Z and methicillin were used in combination in which case at the 12hr 
time point the difference in cfu/ml is still 5-log. By the 24hr time point colony counts of nisin 
and methicillin, in combination, treated cells were equal to that of untreated cells, however, 
colonies appear to be smaller indicating that the cells are stressed (Figure 3.4 B). 
An additional assay was carried out in order to determine if the benefits of combining 
nisin Z and methicillin extended to when applied to an ex vivo porcine skin model. The results 
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showed that when nisin Z and methicillin were applied to pig skin that had been infected with 
MRSA ST291, at a concentration of 1g/ml and 32g/ml respectively, that there was a greater 




 Considering the effects of antibiotic over-exposure in the environment, in agriculture 
and in healthcare settings on antibiotic resistance, alternative therapeutic options need to be 
explored. The potential of using bacteriocins as biological therapeutics is attracting an 
increasing amount of attention due to their low toxicity and highly potent and stable nature. 
Previous studies involving combinations of bacteriocins and other antimicrobials have shown 
promise; such as the bacteriocin duracin 61A demonstrating synergistic activity against MRSA 
(S. aureus ATCC 700699) when used in combination with vancomycin, and the synergistic 
effect between nisin and penicillin when used in combination against multiple E. faecalis 
strains60,61. In this study we further examined the use of bacteriocins in combination with 
different antibiotics for the treatment of various pathogens. An initial screening for 
antimicrobial activity using a bank of bacteriocins against five different strains of bacteria 
highlighted the potential of two bacteriocins, nisin Z and lacticin 3147, for antibiotic 
combination studies. Nisin Z demonstrated the highest level of activity against C. acnes LMG 
16711 and otherwise comparable activity to the two other bacteriocins with the highest level 
of activity against E. faecium UCC2 (nisin F and lacticin 3147). Lacticin 3147 demonstrated 
the highest level of activity against E. faecium UCC1 and C. xerosis DPC 5629 and exhibited 
comparable activity to the two other bacteriocins with the highest level of activity against E. 
faecium UCC2 (nisin F and nisin Z). For these reasons nisin Z and lacticin 3147 were both 
chosen for further combination studies with a number of antibiotics. It is also noteworthy that 
in this initial screen no bacteriocin demonstrated activity against MRSA ST291.  
 MIC results demonstrated that all strains used in this study remain sensitive to both 
penicillin G and vancomycin, with the exception of MRSA ST291 which exhibited resistance 
to penicillin G. In the case of C. acnes LMG 16711 a higher concentration of bacteriocin was 
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required to produce an antimicrobial effect than antibiotic. However, for the other four strains 
tested some bacteriocins proved to be more effective than the antibiotics tested, as was in the 
case of both nisin Z and lacticin 3147 against E. faecium UCC1 and E. faecium UCC2 and 
lacticin 3147 against C. xerosis DPC 5629.  
In this study the amount of antibiotic, such as vancomycin or penicillin (associated with 
toxicity in patients and a growing concern of resistance), required to kill the pathogens was 
reduced by the addition of bacteriocins such as nisin Z and lacticin 3147, which have exhibited 
no adverse effects in animals to date62. Both nisin and lacticin 3147 produce antimicrobial 
activity by interacting with lipid II, forming pores in the cell membrane and inhibiting cell wall 
synthesis. These pores are thought to facilitate intracellular access to antibiotics allowing them 
to act more effectively and thus producing a synergistic effect. The increased efficiency of 
either penicillin G or vancomycin when used in combination with lacticin 3147 was observed 
using growth curves (Figure 3.2). The antimicrobial activity of penicillin G and vancomycin 
against each bacterial strain tested was significantly strengthened in the presence of lacticin 
3147. Over the 48hr period, or 100hr period in the case of C. acnes LMG 16711, the level of 
bacterial growth when treated with either lacticin 3147 or antibiotic alone was substantial when 
compared to the lack of growth when treated with a combination. In the case of C. acnes LMG 
16711 the concentration of penicillin G could be reduced from 0.2g/ml to 0.015g/ml when 
used in combination with 1.5g/ml lacticin 3147. For both E. faecium strains penicillin G could 
be reduced from 3.56g/ml to 0.22g/ml when used in combination with 1.8g/ml lacticin 
3147 (E. faecium UCC1) or 2.4g/ml (E. faecium UCC2). The concentration of vancomycin 
could be reduced from 0.91g/ml  to 0.45g/ml when used in combination with 1.2g/ml  
lacticin 3147 for the treatment of C. xerosis DPC 5629, and from 1.81g/ml to 0.91g/ml when 
used in combination with 38.5g/ml lacticin 3147 for the treatment of MRSA ST291. Penicillin 
acts by binding to a penicillin-binding protein (PBP), DD-transpeptidase, preventing cell wall 
 145 
synthesis, whereas vancomycin acts by binding to D-alanyl-D-alanine containing peptides and 
preventing their incorporation into the peptidoglycan matrix of the cell wall, thus preventing 
cell wall biosynthesis63,64. The bacteria, after encountering multiple approaches of attack on its 
cell wall from both lacticin 3147 and antibiotic, cannot recover as easily as with one approach 
and thus a higher rate of death occurs. This can be seen in both the growth curves and time-kill 
assays (Figures 3.2, 3.3), where it is evident that the same concentration of either lacticin 3147 
or antibiotic (penicillin G or vancomycin) have displayed greater antimicrobial activity, to a 
varying degree, against each indicator strain when used in combination than either used alone. 
Combining antimicrobials with different antimicrobial mechanisms rather than antimicrobials 
with the same or similar modes of action in general yield better antimicrobial results along with 
reducing the prospect of resistance development61,65,66. Previous studies have shown that 
combining vancomycin, which by inhibiting cell wall synthesis decreases access to lipid II, 
with a bacteriocin that interacts with lipid II, such as lacticin 3147 or nisin, can decrease the 
possibility of synergistic antimicrobial activity61. Therefore combining lacticin 3147 or nisin Z 
with an antibiotic such as penicillin, which attacks by a different pathway, may be a better 
approach to achieve synergy.    
Along with reducing the amount of antibiotic required, this study focused on the 
possibility of using antibiotics, to which bacteria have already established resistance, in 
combination with bacteriocins in an effort to reclaim the use of such antibiotics. Due to 
MRSA’s clinical significance, methicillin was used as the subject for investigation in 
combination with the bacteriocin nisin Z for the treatment of MRSA. Nisin and methicillin 
attack the cell wall synthesis pathway at different points, thus potentially allowing them to 
generate a greater disruption within the cell wall when used together. FIC results confirm 
partial synergy between nisin Z and methicillin against MRSA ST291 (Table 3.3). FIC results 
also show a lack of synergy between nisin Z and vancomycin, possibly due to vancomycin 
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decreasing the accessibility of lipid II to nisin Z (Table 3.3). Time-kill assays were used to 
further analyse nisin Z and methicillin’s activity against MRSA ST291 over a 24hr period, with 
a decrease in growth when used in combination compared to either alone. MRSA ST291, when 
treated with either nisin Z or methicillin, reached the same level of growth as the untreated 
control between 9 and 12hrs, whereas it did not reach the same level of growth until ~24hrs 
when treated with both (Figure 3.4 A). Despite the fact that the cfu/ml of the combination-
treated cells was equivalent to that of cells treated with either alone the colonies were much 
smaller, indicating they were stressed (Figure 3.4 B). Interestingly the cfu/ml of the cells 
treated alone continually rose over the 24hr period, however the cfu/ml of the combination 
treated cells declined until the 9hr point at which it then began the rise, indicating that the 
combination of nisin Z and methicillin worked optimally up until the 9hr time point. 
 The enhanced antimicrobial activity of nisin Z and methicillin when used in 
combination was further analysed for its potential clinical use by means of an ex vivo porcine 
skin model. When applied to MRSA ST291 infected porcine skin the combination of 
antimicrobials (nisin Z and methicillin) had a greater effect than the sum of antimicrobial 
activity of either alone (Figure 3.5). However, the antimicrobial effect of both nisin Z and 
methicillin appear to be reduced when applied to the skin model, with the difference in cfu/ml 
being much less than that achieved in vitro. Nevertheless, a greater antimicrobial effect can 
still be seen, suggesting that the model may need to be optimised and further analysis carried 
out.  
 The exact mechanism by which nisin Z and methicillin produce a synergistic effect 
against MRSA ST291 is still unclear, as MRSAs resistance to methicillin is reliant upon its 
ability to produce the enzyme -lactamase, which results in the digestion of methicillin 
rendering it inactive against MRSA. Further studies need to be done to determine if, in the 
presence of both methicillin and nisin Z, the production of -lactamase is down regulated, 
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possibly as a result of cellular stress, thus allowing for methicillin to again have antimicrobial 
activity against MRSA. Similar studies should be done for when using lacticin 3147 in 
combination with penicillin G against -lactamase producing pathogens. 
With antibiotic resistance becoming of greater concern the need for alternative 
therapies is becoming more prevalent. These in vitro and ex vivo results suggest that 
bacteriocins such as nisin Z and lacticin 3147 may i) aid in prolonging the use of certain 
antibiotics which are under threat of becoming ineffective due to antibiotic resistance and ii) 
be used in combination with currently ineffective antibiotics, like methicillin, to revive the use 
of such antibiotics.   
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Organism MIC (µg/ml) FIC 






Nisin Z / 
methicillin 




1.88 2.50 0.06 (S) 1.25 (S) - - 
E. faecium 
UCC1 
0.26 0.12 0.89 (S) 0.63 (S) - - 
C. xerosis 
DPC 5629 
8.33 0.24 0.63 (R) 0.45 (S) - - 
E. faecium 
UCC2 
0.52 0.48 0.89 (S) 0.63 (S) - - 
MRSA  
ST291 
4.17 3.85 20.00 (R) 0.91 (S) 0.75a 1.01b 
Table 3.3 MIC - Minimum Inhibitory Concentration results of nisin Z, Lacticin 3147, 
Penicillin G and Vancomycin against Gram-positive strains Cutibacterium acnes LMG 16711, 
Enterococcus faecium UCC1, Corynebacterium xerosis DPC 5629, Enterococcus faecium 
UCC2 and MRSA ST291. Resistant (R) and Sensitive (S) values are taken from EUCAST 
clinical breakpoint 2019 report67. FIC – Fractional Inhibitory Concentration results indicate 
apartial synergy and badditive. 
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Figure 3.1 Deferred antagonism results of a bank of various bacteriocins producer strains 
against (A) C. acnes LMG 16711, (B) Enterococcus faecium UCC1, (C) C. xerosis DPC 5629 
and (D) Enterococcus faecium UCC2. Deferred antagonism assays were carried out for MRSA 
ST291 but no zones of inhibition were observed. The zone of inhibition is expressed as the 
diameter of the zones minus the diameter of the ‘spot’ in mm. Blue bars indicate bacteriocins 

















































































































































































































































































































































































































































































































































































































































































































C. xerosis vs Lacticin3147 & Vancomycin














C. xerosis 1.2g/ml Lacticin 3147



















Enterococcus UCC1 vs lacticin3147 & Penicillin G






























C. xerosis vs Lacticin3147 & Vancomycin


































Enterococcus UCC1 vs lacticin3147 & Penicillin G






























− C. acnes LMG 16711               − 1.5 μg/ml Lacticin3147 
− 0.015 μg/ml Penicillin G      − 1.5 μg/ml Lacticin 3147 & 
− 0.2 μg/ml Penicillin G 0.015 μg/ml Penicillin G  




















Figure 3.2 Growth curve results of (A) penicillin G (0.015g/ml or 0.2g/ml) and lacticin 
3147 (1.5g/ml) against C. acnes LMG 16711 (B) vancomycin (0.45g/ml or 0.91g/ml) and 
lacticin 3147 (1.2g/ml) against C. xerosis DPC 5629, (C) penicillin G (0.22g/ml or 
3.56g/ml) and lacticin 3147 (1.8g/ml) against E. faecium UCC1, (D) penicillin G (0.22g/ml 
or 3.56g/ml) and lacticin 3147 (2.4g/ml) against E. faecium UCC2 and (E) vancomycin 
(0.91g/ml  or 1.81g/ml) and lacticin 3147 (38.5g/ml) against MRSA ST291.  
Enterococcus UCC2 vs lacticin 3147 & Penicillin G












E. faecium  UCC2 2.4g/ml Lacticin 3147



















MRSA vs lacticin3147 & Vancomycin














MRSA ST291 38.5g/ml Lacticin 3147



















Enterococcus UCC2 vs lacticin 3147 & Penicillin G
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             C. acnes  (1 and 3 hrs post treatment)



















                Enterococcus faecium  UCC1 (1and 3 hrs post treatment)






















                C. xerosis  (1 and 3 hrs post treatment)







































Figure 3.3 Time-kill results of (A) penicillin G (0.176µg/ml) and lacticin 3147 (7.5µg/ml) 
against C. acnes LMG 16711 (B) penicillin G (3.56µg/ml) and lacticin 3147 (1.80µg/ml) 
against E. faecium UCC1, (C) vancomycin (0.91µg/ml) and lacticin 3147 (1.2µg/ml) against 
C. xerosis DPC 5629, (D) penicillin G (3.56µg/ml) and lacticin 3147 (1.44µg/ml) against E. 
faecium UCC2 and (E) vancomycin (0.91µg/ml) and lacticin 3147 (11.55µg/ml) against 
MRSA ST291.  
                Enterococcus faecium UCC2   (1 and 3 hrs post treatment)






















MRSA ST291  1 and 3 hrs post treatment













































































Figure 3.4 (A) Time-kill plate counts of MRSA ST291 3, 6, 9 and 12hrs post treatment with 
nisin Z (1g/ml) and methicillin (32g/ml). (B) Examination of MRSA ST291 colony 
morphology 24hrs untreated and post treatment with nisin Z and methicillin.  
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Figure 3.5 Ex vivo porcine skin model plate counts of MRSA ST291 3hrs post treatment with 
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3  Chapter IV 
 
 
Nisin Z induces apoptotic and autophagic cell death in colorectal and oesophageal 




In recent years the potential use of bacteriocins such as nisin as anti-cancer agents has 
received some attention. Nisin Z is a naturally occurring variant of nisin which has been safely 
used for many years as a food preservative. This study explored the anti-cancer effects of nisin 
Z on six different cell lines (HCT116, HT29, SW620, Caco2, OE19 and KYSE450). Nisin Z 
induced apoptotic cell death in all four colorectal cell lines and autophagic cell death in 
oesophageal cell lines. In addition, multiple primer sets were generated and qRT-PCR was used 
to examine the apoptotic and autophagic pathways of HCT116 and KYSE450. Apoptotic 
activity in nisin Z treated HCT116 cells was tightly controlled by means of upregulating 
caspase-9 (intrinsic pathway) along with the upregulating the anti-apoptotic Bcl-2 protein. In 
the case of nisin Z treated KYSE450 cells the upregulation of the Beclin gene confirmed 
autophagy induction. This data indicates that nisin Z induces programmed cell death by means 
of either apoptosis or autophagy in at least six difference cancer cell lines. Given its GRAS 




With over 200 types and approximately 14.1 million new cases reported globally each 
year, it is not surprising that cancer is one of the most extensively researched areas in 
medicine1. Over the last few decades the number of global diagnoses has steadily increased 
and is expected to rise to 23.6 million new cases by the year 20301. This increase is due to a 
number of factors which include a globally aging population, increasingly unhealthy lifestyles, 
tobacco smoking, and environmental factors among others2–4. In contrast to this, the number 
of cancer-related deaths has decreased from 49.72% to 36.39% (2015)5. According to the 
World Health Organisation (WHO), 1 in 6 mortalities are attributed to cancer, making it the 
second leading cause of death worldwide6.  
In 2018 9.6 million deaths were cancer related, with 862,000 of these due to colorectal 
cancer (8.98%)6. Adenocarcinomas account for approximately 96% of all colorectal cancers 
and affect the mucus forming cells which aid in the internal lubrication of the colon and 
rectum7. Although the survival rate has increased in recent decades, it remains the third most 
commonly diagnosed cancer in men and second in women6,8–10. The prognosis for a patient can 
range from a five year survival rate of as high as 92% to as low as 10%, depending on the 
cancer stage at the time of diagnosis11,12. Oesophageal cancer has the sixth highest mortality 
rate of all cancers and a five year survival rate of 40% to 11% depending on the stage13. The 
expected increase in incidence of colorectal cancer of up to 60% by the year 2030 and the 
relatively low survival rate for oesophageal cancer accentuates the need for improved or novel 
therapies10. 
Traditionally the methods used to treat cancer include chemotherapy, radiotherapy, 
chemo-radiotherapy and surgery. They are known to have a variety of side effects ranging in 
severity including, but not limited to, nausea/vomiting, hair loss, weight loss/gain, neutropenia, 
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stomatitis, diarrhoea, and aggravated insomnia14–16. This study aims to explore the idea of using 
bacteriocins as alternative therapeutics for the treatment of colorectal and oesophageal 
carcinomas.  
Bacteriocins are antimicrobial peptides and have traditionally been used within the food 
industry as a food preservative. Recently nisin Z was shown to have a significant effect on 
floor-of-mouth oral cancer and head and neck squamous cell carcinoma (HNSCC) by reducing 
tumour volume and enhancing apoptosis, and blocking cell proliferation respectively, thus 
showing the potenitial for bacteriocins as a therapeutic for a number of cancers17,18. The 
theoretical therapeutic dose of nisin in humans was calculated at 66.7mg/kg body weight/day 
when converted from a 800mg/kg body weight/day dose in mice, which does not exceed the 
LD50 (lethal dose, 50%) reported in rodents7– 9. When treated with 800mg/kg body weight/day 
for 3 weeks, tumour sizes in mice decreased by 5.8% with normal organ histology and no 
apparent inflammation, fibrosis or necrosis18. In addition, the FDA has approved the no-
observed-adverse-effect-level (NOAEL) of <250ppm of nisin in food and the highest tested 
dose of nisin, 83.25mg/kg of diet, has been accepted19. 
Certain bacteriocins have demonstrated  selective cytoxicity to various cancer cell lines 
which may be attributed to a number of factors. One such factor is that cancer cell membranes 
are known to have a predominantly negative charge due to an increase in the number of 
negatively charged phospholipids, such as phosphatidylserine, on the outer surface21. As 
bacteriocins are naturally positively charged they may preferentially bind to the negatively 
charged cancer cells over neutral healthy cells. Other factors include an increase in membrane 
fluidity of cancer cells thus allowing for membrane destabilization, and an increase in surface 
area on cancer cells due to a greater number of microvilli, allowing for more bacteriocin 
binding21. 
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This potential new application of the well-studied nisin has attracted much interest, 
however its efficacy in cancers of the gastrointestinal tract has not yet been comprehensively 
evaluated. In this study, the potential efficacy of nisin was assessed as a treatment using six 
cell lines, derived from human tumours of the colon and oesophagus. Following treatment of 
the cells with nisin, pathways associated with apoptosis, autophagy and necrosis were analysed 
using a variety of experimental methods including morphological examination, flow 
cytometry, confocal microscopy and quantitative real-time polymerase chain reaction (qRT-
PCR).   
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3.3 Experimental procedures 
 
HCT116, HT29, SW620 and Caco2 cancer cell lines were acquired from ATCC, and 
OE19 and KYSE450 cell lines were from the UCC cell line collection. Cell lines grown in 
Dulbecco’s Modified Eagle Medium (DMEM) were supplemented with 10% foetal calf serum 
(FCS). OE19 cells were grown in Rosewell Park Memorial Institute-1640 (RPMI) medium 
supplemented with 10% FCS and 1% L-glutamine. KYSE450 cells were grown in a 1:1 ratio 
of RPMI-1640 and Hams F12 nutrient mixture (HEPES modified without L-glutamine), 
supplemented with 10% FCS and 1% L-glutamine. All cell lines were incubated at 37C in a 
humidified atmosphere with 5% CO2 in air. 
 
Cell line Origin Media 
HT29 Colorectal adenocarcinoma 
DMEM (supplemented with 10% 
FCS) 
OE19  
Oesophageal squamous cell 
carcinoma  
RPMI-1640 (supplemented with 
10% FCS and 1% L-glutamine) 
HCT116  Colorectal carcinoma  
DMEM (supplemented with 10% 
FCS) 
Caco2  Colorectal adenocarcinoma 
DMEM (supplemented with 10% 
FCS) 
SW620  Colorectal adenocarcinoma 
DMEM (supplemented with 10% 
FCS) 
KYSE450  
Oesophageal squamous cell 
carcinoma  
1:1 RPMI -1640 & Hams F12 
(supplemented with 10% FCS and 
1% L-glutamine) 
Table 4.1 Cell lines used in this study. DMEM (Sigma), RPMI-1640 without phenol red 
(Sigma), Hams F12 nutrient mixture (Sigma), and FCS (Sigma).  
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3.3.1 MTT assay 
MTT is a colorimetric assay used to determine cell metabolic activity and thus, under 
defined conditions, cell viability. Metabolically active cells enzymatically reduce yellow 
tetrazolium to purple formazan, which can then be dissolved in DMSO in order to measure an 
absorbance reading.  
At a cell density of 1x104 cells per well were seeded into the wells of a 96 well flat-
bottomed tissue culture plate (Sarstedt) and allowed to attach overnight at 37˚C in a humidified 
atmosphere with 5% CO2. Following attachment, the cells were treated with either 800µg/ml 
nisin Z or nisin 1-28 (a truncated form of nisin shown to have 100-fold less activity against 
certain bacteria such as L. Lactis) (with DMEM as an untreated control) in triplicate and 
incubated at 37°C with 5% CO2 for 96 hrs22. The media was subsequently removed by 
aspiration prior to adding 200µl of MTT (Thiazolyl Blue tetrazolium Bromide) (Sigma) 
solution (2mg/ml in serum free DMEM). Following 4hrs incubation (37˚C in a humidified 
atmosphere with 5% CO2) the MTT solution was removed by aspiration and 200µl of DMSO 
added to each well ensuring homogeneity by gentle mixing. The absorbance at OD570nm was 
measured using a SpectraMax MP3 spectrophotometer and plotted as a precentage of untreated 
controls.    
 
3.3.2 Colony Formation assay 
Cells were seeded into a 24 well plate to a cell density of 1x105 per well and allowed 
attach overnight at 37˚C in a humidified atmosphere with 5% CO2. Cells were treated with 
800µg/ml nisin Z (with DMEM as an untreated control) in duplicate and allowed incubate for 
either 72hrs or 96hrs. Following incubation the cells were harvested by collecting the 
supernatant and trypsinising attached cells, both of which were pooled. Cells were seeded to a 
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density of 2x103 into a 6 well plate in triplicate and incubated until colonies were visible in the 
untreated control by macroscopic examination. 
Following the removal of media by aspiration the cells were fixed with methanol for 
10mins, washed with PBS and stained with Pro Diff II (Braidwood Laboratories) stain for a 
further 10mins. The cells were then gently rinsed with H2O and allowed to dry before 
photographing. Colonies were enumerated using ImageJ software and colony numbers of 
treated cells were plotted as a percentage of untreated cells. 
 
3.3.3 Preparation of cells for morphological examination using cytospin 
Cells were seeded into a 6 well plate at a density of 5x105 cells per well in triplicate 
and allowed attach overnight at 37˚C in a humidified atmosphere with 5% CO2. Following 
incubation cells were treated with either 600µg/ml or 800µg/ml nisin Z (with DMEM as an 
untreated control) in duplicate and incubated for 72hrs or 96hrs. Following incubation the cells 
were harvested by collecting the supernatant and trypsinising attached cells. Approximately 
10,000 cells were spun onto glass slides (Cytopsin 4, Thermo Scientific) at 400rpm for 2mins. 
The cells were then fixed with methanol for 5mins and stained with Pro-Diff (Braidwood 
Laboratories). Cells were analysed using light microscopy at 40X. 
 
3.3.4 Flow cytometry 
The percentage of apoptotic cells induced by nisin Z treatment was determined by flow 
cytometry. Cells were seeded into a 24 well plate at a cell density of 5x104 cells per well in 
triplicate and allowed attach overnight at 37˚C in a humidified atmosphere with 5% CO2. 
Following incubation the cells were treated with 0.05mM 5-FU (positive control) or 800µg/ml 
nisin Z (with DMEM as an untreated control) and incubated for 96hrs. Following incubation 
the cells were harvested by collecting the supernatant and trypsinising the remaining attached 
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cells. Cells were pelleted by centrifugation at 130rcf for 10mins and resuspended in 500µl 1X 
binding buffer followed by the addition of 5µl of propidium iodide (PI) (50µg/ml) and 5µl of 
Annexin V-FITC (Apoptosis Detection Kit, Abcam) before incubation at room temperature for 
5mins in the dark. The suspensions were transferred to plastic cytometry tubes for analysis by 
flow cytometry. Samples were analysed using a BD Celesta Fluorescence Activated Cell Sorter 
(FACS). 10,000 events were analysed per sample using the 488 (blue) laser, for FITC an 
excitation/emission of 494/519nm was used and 493/636nm for PI. Resulting data was 
analysed using FACS Diva software. Gating limits (set up to exclude cellular debris), laser 
position, side scatter and forward scatter plots were established first by analysing untreated 
controls. Test samples were then analysed using these parameters. 
 
3.3.5 Confocal microscopy 
Cells to be assayed were seeded into a a 24 well plate at a density of 5x104 per well in 
triplicate and allowed attach overnight at 37˚C in a humidified atmosphere with 5% CO2. 
Following incubation the cells were treated with either 6.5g/L 5-FU (positive control) or 
800µg/ml nisin Z (with sterile DMEM as an untreated control) and subsequently incubated 
(37˚C in a humidified atmosphere with 5% CO2) for 72hrs. Following incubation, the cells 
were harvested by collecting the supernatant and trypsinising the remaining attached cells. 
Cells were prepared for live cell analysis by confocal microscopy using CYTO-ID green 
detection reagent and Hoechst 33342 nuclear stain (CYTO-ID autophagy detection kit, Enzo). 
Following incubation at (37˚C in a humidified atmosphere with 5% CO2) for 30mins the cells 
were pelleted by centrifugation at 100rcf for 10mins and resuspended in 100µl assay buffer. 
Using a 63X lens on a laser scanning microscope (LSM) 5 exciter (Zeiss LSM 5 Exciter, Zeiss, 
Germany), the cells were imaged using both an Argon LGK 7812 Lasos laser (fluorescence 
detected at wavelength 488nm, 25.0mW) and Diode 405-25 NT405 Carl Zeiss laser 
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Cells to be assayed were seeded into a 24 well plate at a density of 1x105 per well in 
triplicate and allowed attach overnight at 37˚C in a humidified atmosphere with 5% CO2. 
Following incubation the cells were treated with 800µg/ml nisin Z (with sterile DMEM as a 
negative control) and incubated (37˚C in a humidified atmosphere with 5% CO2) for 96hrs. 
Following incubation the cells were harvested by collecting the supernatant and trypsinising 
the remaining attached cells. RNA was extracted from the cells (Rneasy mini kit, Qiagen) 
before checking the quality (2100 Bioanalyser system, Agilent) and quantity (Qbit fluorometric 
RNA HS assay kit, InvitrogenTM) of each RNA sample. Each sample was converted into cDNA 
using Reverse Transcription PCR (RT-PCR). RT-PCR was executed with a total of 20l 
comprised of 4l 5X transcriptor buffer (Roche), 2l dNTP nucleotide mix (10mM) (Roche), 
1l Transcriptor Reverse Transcriptase and Protector Rnase inhibitor mix (Roche), 3l 
Random primer p(dN)6 (Roche) and 10l RNA sample. Cycling conditions were as follows: 
25C for 10mins, 55C for 30mins and 85C for 5mins. Samples were then diluted using 80l 
PCR-grade H2O and 20l of cDNA sample.  
Quantitative real-time PCR (qRT-PCR) analysis was performed on each sample using 
a LightCycler 480 (Roche) machine and software (release 1.5.0). For the PCR reaction a total 
of 10l comprising of 5l Sybr green (2X SensiFAST SYBR Hi-ROX Kit, Labgene), 0.5l of 
both forward and reverse primers (10M) (Table 4.2) (Sigma Aldrich), 1l PCR-grade H2O 
and 3l cDNA sample was used. qRT-PCR conditions were as follows: pre-incubation cycle 
of 50C for 2mins followed by 45 cycles of 95C for 10secs, 60C for 45secs and 72C for 
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1sec and a melting temperature of 95C. The endogenous expression of beta actin was used as 
an internal reference. Data normality was determined using a Shapiro-Wilk test and futher 
analysis was performed using a paired t-test.  
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3.4 Results  
 
3.4.1 MTT assay 
 An MTT assay performed on KYSE450 and HCT116 cell lines 96hrs post-treatment 
with 800g/ml nisin 1-28 (shown to be up to 100-fold less active against various bacterial 
strains) showed almost no effect on survival with a % survival >80% in the case of both cell 
lines (Figure 4.1). This is in contrast to the effects obseved when treated with nisin Z, with 
significant decreases in survival with a cell survival of <50% being recoreded in the case of 
both cell lines (Figure 4.1). 
 
3.4.2 Colony Formation assay 
Cell recovery was measured for each cell line by means of colony formation assays of 
morphologically intact cells (Figures 4.2, 4.3). Recovery levels decreased in all six cell lines 
treated with either 600g/ml or 800g/ml of nisin Z at both 72 and 96hrs, compared to an 
untreated control. Four of the six cell lines demonstrated a significant decrease in recovery at 
96hrs post-treatment, two at a concentration of 800µg/ml (KYSE450 and SW620) and two 
showed a marked decrease in recovery at the lower concentration of 600µg/ml (OE19 and 
HT29). HCT116 cells were more sensitive to nisin Z at a concentration of 600g/ml 72hrs post 
treatment than when treated for 96hrs. Recovery levels of Caco2 cells were lower when treated 
with nisin Z at a concentration of 800g/ml than 600g/ml, however, recovery levels 96hrs 
post treatment were comparable to 72hrs of treatment. Of all the cell lines, KYSE450 proved 
to be the most sensitive to nisin Z treatment (800g/ml), as evidenced by a significant decrease 
in colony count following staining at both 72 and 96hrs (Figures 4.2 A, B, 4.3 C) 
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3.4.3 Morphological examination 
 Post treatment with nisin Z (600g/ml and 800g/ml) for both 72 and 96hrs, cells were 
prepared via cytospinning, for morphological examination using microscopy techniques. 
Membrane blebbing in HT29, SW620, Caco2 and HCT116 cell lines (Figures 4.4 A, C, D, F), 
and autophagic vacuoles in the cytoplasm of OE19 and KYSE450 cells lines (Figures 4.4 B, 
E) were observed. Membrane blebbing or autophagic vacuoles were observed in each cell line 
at both time points (72 and 96hrs of treatment) and with both concentrations of nisin Z 
(600g/ml and 800g/ml). 
 
3.4.4 Flow cytometry  
Flow cytometry was performed on nisin Z treated cells (800g/ml for 96hrs) to determine the 
mode of cell death. Healthy cells predominantly occupy the lower left quadrant of the scatter 
plot, indicating that they haven’t bound PI or FITC-tagged AnnexinV. FITC-tagged AnnexinV 
will bind early apoptotic and late apoptotic cells, with late apoptotic cells also binding PI. Cell 
stained only with PI are considered to be necrotic.   
Nisin Z treated CACO2 cells contain an increased population of PI+AnnexinV+ and 
AnnexinV+ cells compared to an untreated control, 34.8% and 3.8% respectively (Figure 4.5 
D), suggesting an apoptotic mode of cell death.  
In the case of HCT116, when compared to untreated control, Nisin Z-treated cell 
populations presented as late apoptotic (30.4%) with a smaller population showing as early 
apoptotic (4.7%) (Figure 4.5 B). Nisin Z (800g/ml) treated SW620 cells display a similar shift 
towards both late (66.0%) and early (20.1%) apoptosis; even more so than the 5-FU treated 
cells of 56.4% and 15.3% respectively (Figure 4.5 C).  
In comparison to the untreated population, the majority of nisin Z (800g/ml) treated 
KYSE450 cells present as necrotic (14.6%) and late apoptotic (49.2%) (Figure 4.5 F).  A 
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similar trend was seen in the FACS analysis of Nisin Z-treated OE19 cells. 9.7% of the 
population of treated cells presented as necrotic and 27.3% presenting as late apoptotic (Figure 
4.5 E). The majority of nisin Z (800g/ml) treated HT29 cells, when compared to untreated 
cells, present as late (22.4%) and early apoptotic (12.7%) (Figure 4.5 A).   
 
3.4.5 Confocal microscopy examination 
 Confocal laser scanning microscopy (CLSM) was used to image autophagic vacuoles 
of nisin Z (800g/ml) treated KYSE450 and OE19 cell lines (Figure 4.6). Hoechst 33342 
nuclear stain, which preferentially binds to adenine-thymine regions of eukaryotic DNA, was 
used for visualising cell nucleoli (blue fluorescence), whereas CYTO-ID green detection 
reagent was used to identify the accumulation of autophagic vacuoles through specific labelling 
(yellow fluorescence). Distinctive autophagic vacuoles accumulated in nisin Z (800g/ml) 
treated KYSE450 and OE19 cell lines when compared to untreated control (Figure 4.6). 
Autophagic vacuoles can also be seen in 5-FU (positive control) treated cell. 
 
3.4.6 qRT-PCR 
 qRT-PCR analysis was employed to determine the apoptotic and autophagic pathways 
taken by HCT116 and KYSE450 cells lines. In the case of nisin Z (800g/ml) treated HCT116 
cells caspase-9 and Bcl-2 were both upregulated when compared to the untreated control, 
whereas there was no statistically significant change in the expression levels of CHOP, 
caspase-8 and caspase-12. Nisin Z (800g/ml) treated KYSE450 cells, showed upregulation of 




Traditionally nisin has been used as a food preservative, but recently it has become the 
subject of much interest with regards to its use as a therapeutic against a range of clinically 
significant bacteria, and more recently for its potential as a therapeutic for certain 
cancers17,18,23. In particular HNSCC cell lines showed a significant reduction in tumour volume, 
enhanced apoptosis and blocked cell proliferation, when treated with nisin Z17,18. Here we 
investigate whether the therapeutic effects of nisin can extend to a panel of oesophageal and 
colorectal cancer cells lines, namely HCT116, SW620, HT29 Caco2, KYSE450 and OE19 
(Table 4.1). 
Initial MTT assays were performed on two different cell lines to determine the  effect 
of nisin Z on each cell line in comparison to the nisin variant nisin 1-28, which is known to be 
100-fold less active against certain bacteria22. A significant decrease in cell survival was seen 
in cells treated with nisin Z in comparison to cells treated with nisin 1-28 (Figure 4.1). This 
suggests that the truncated variant’s (nisin 1-28) activity against selected cell lines (KYSE450 
and HCT116) is also decreased, along with the specific structure of nisin Z playing a role in 
how effective the peptide is against these specific cancer cells lines.   
Colony formation assays were employed to determine the ability of each cell line to 
recover from nisin Z treatment, using both 600g/ml and 800g/ml, at two different time points 
(72 and 96hrs). A notable degree of variability was seen between each cell line in terms of 
recovery after 96hrs of treatment, but less so at 72hrs of treatment (Figure 4.2). KYSE450 and 
OE19 cell lines have previously been shown to induce autophagy when stressed24. Autophagy 
is a highly conserved survival response to unfavourable conditions, in which cellular 
components are degraded and recycled and is genetically regulated by a group of genes called 
the ATG genes. Autophagy can play a role in achieving a homeostatic state in normal cells, but 
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it has previously been shown to aid cancer cell survival in the presence of chemotherapeutic 
drugs, including 5-FU treated KYSE450 and OE19 cell lines24. In contrast to this our results 
display an increased level of autophagy but a decrease in percentage recovery of nisin Z treated 
KYSE450 and OE19 cell lines. Out of the six cell lines tested KYSE450 showed the lowest 
rate of recovery and OE19 the third lowest rate of recovery, thus provoking the idea that nisin 
Z stimulates an autophagy-linked type II programmed cell death (PCD). Previous studies have 
shown that autophagy alone may be able to induce cell death (type II PCD), however other 
studies have shown that autophagy more commonly increases dramatically before cell death 
by means of apoptosis (type I PCD), leading to the question of whether nisin Z causes cell 
death by autophagy alone or apoptosis, or both. Regulation of autophagy and apoptosis has 
been shown to overlap, with cells either positively or negatively stimulating the interactions 
between the anti-apoptotic protein Bcl-2 and the autophagy protein Beclin 125. In nutrient-rich 
condition Bcl-2 can inhibit the autophagic activity of Beclin 1 thereby inhibiting autophagy; 
this interaction can also be blocked, thus allowing for autophagic activity25.   
 Preliminary morphological examination determined the mode of cell death following 
treatment with nisin Z for both 72 and 96hrs (600g/ml and 800g/ml). This revealed that 
nisin-treated HT29, Caco2, SW620 and HCT116 cells lines had obvious cytoplasmic 
membrane blebbing along with some chromatin condensation, which are both morphologically 
distinguishable features of apoptotic cells (Figures 4.4 A, C, D, F). Cell lines OE19 and 
KYSE450 had numerous vacuoles within the cytoplasm when compared to untreated control, 
indicating autophagic activity (Figures 4.4 B, E). To further determine mode of cell death PI 
and Annexin V FITC stained cells were analysed by flow cytometry. PI was used to 
distinguished necrotic cells, whereas Annexin V conjugated to green-fluorescent FITC dye was 
used to identify apoptotic cells by detecting phosphatidylserine that is exposed on the cell 
surface of apoptotic cells. SW620 cells gave the most striking results with 21.1% of cells 
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appearing as early apoptotic and 66% as late apoptotic, which was a greater number than the 
5-FU treated positive control. For treated HT29 cells 35.1% were either early or late apoptotic. 
Consistent with the colony formation assay results, SW620 and KYSE450 cell lines had the 
fewest number of cells remaining in the healthy quadrant, 13.1% and 33.1% respectively. 
HT29, HCT116, SW620 and Caco2 cells lines show results consistent with apoptotic mode of 
cell death. In the case of KYSE450 cell line, nisin Z treated cells did not display a strong 
apoptotic profile despite the high level of cell death observed in other assays (Figure 4.5). 
KYSE450 showed a high sensitivity to nisin Z in the clonogenic assays, and displayed an 
abundance of cytoplasmic vacuoles in morphological assays and a weak apoptotic profile when 
examined by flow cytometry.  It is possible that KYSE450 cells are dying by means of 
autophagy or type II PCD. OE19 cell lines had a high level of cells present as apoptotic.  With 
morphological examination clearly showing cytoplasmic vacuoles, it is possible that cells are 
under extreme stress and are producing vacuoles for attempted survival before dying by means 
of apoptosis. It has been shown in previous studies that some cell lines, before dying by 
apoptosis produce vast amount of vacuoles in an attempt to undergo autophagy recycling in 
order to survive25.  
 Autophagic vacuoles were distinguished from accumulated lysosomes using confocal 
laser scanning microscopy (CLSM), further establishing autophagic activity within OE19 and 
KYSE450 cell lines. Nisin Z and 5-FU treated cells were stained with CYTO-ID green 
detection reagent and Hoechst 33342 nuclear stain (CYTO-ID autophagy detection kit, Enzo). 
Both OE19 and KYSE450 display autophagic vacuoles when compared to the untreated control 
(Figure 4.6). In the untreated controls, there is either a complete absence or significantly fewer 
numbers of autophagic vacuoles.  A small number of autophagic vacuoles is normal within 
healthy cells as they can play a part in maintaining population homeostasis as mentioned 
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previously24. However, in 5-FU or nisin Z treated cells there is an obvious increase in the 
number of accumulated autophagic vacuoles, suggesting acute cell stress. 
 qRT-PCR was used to determine the apoptotic and autophagic pathways taken by 
HCT116 and KYSE450 cell lines. Chemotherapy drugs have been shown to activate various 
different pathways within cancer cells leading to apoptosis, such as the intrinsic and/or extrinsic 
pathways, and a failure to do so may lead to treatment resistance26,27. Caspases, important 
apoptosis effector molecules within the extrinsic and intrinsic pathways, can be activated at 
either a specific receptor or mitochondria, both ultimately initiating a caspase cascade leading 
to apoptosis27. Caspase-8, involved in the extrinsic pathway, can be activated by the stimulation 
of receptors, such as Fas and TRAIL (Figure 4.8), resulting in the activation of apoptosis 
through the cleavage of the downstream effectors such as caspase-327. Caspase-9 can also 
activate caspase-3 to induce apoptosis by means of the intrinsic pathway. This entails the 
release of an apoptogenic factor, such as cytochrome c which when released into the cytosol 
forms an apoptosome complex with Apaf-1 and caspase-9 (Figure 4.8)27. Endoplasmic 
reticulum stress can also be involved in multiple apoptotic pathways, including an unfolded 
protein response (UPR) pathway and a caspase-12 involved pathway (Figure 4.8)27,28.  
In the case of nisin Z treated HCT116 cells, the transcription of the caspase-9 gene 
involved in the intrinsic pathway, was upregulated in addition to the anti-apoptosis protein, 
Bcl-2. None of the other genes involved in the extrinsic or UPR pathways were upregulated, 
suggesting that nisin Z induced an intrinsic apoptosis pathway in HCT116 cells. Due to the 
colony formation assay, macroscopy and flow cytometry results displaying partial apoptotic 
activity, and the upregulation of the protein caspase-9, the anti-apoptosis protein Bcl-2 seems 
to be playing an active role in protecting the cells from nisin Z-induced apoptosis.  
The protein Beclin, previously shown to be associated with the induction of autophagy 
cell death in KYSE170 cells, was also upregulated in nisin Z treated KYSE450 cells29. 
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However, the autophagy associated protein BNIP3 was significantly down regulated in 
KYSE450 cells, indicating that an alternative mechanism must have been adopted to achieve 
autophagy than in the case of ethyl-3,4-dihydroxybenzoate treated KYSE170 cells29. 
KYSE450 cell lines have also previously been shown to enter an acute state of autophagy 
before initiating apoptotic cell death, therefore it is still unclear whether nisin Z treated 
KYSE450 cells experience a heightened state of autophagy before ultimately being killed by 
apoptosis or die from autophagy alone. 
 In recent years bacteriocins such as nisin have been shown to produce cytotoxicity in 
various cancer cell lines both in vitro and in vivo29. With an enhanced expression of negatively 
charged molecules on their cell surface, cancer cells can be susceptible to cytotoxic activity 
produced by positively charged bacteriocins21,30. In this study nisin Z demonstrates in vivo 
cytotoxic activity in the form of either apoptosis or autophagy in six different cancer cell lines 
of either the esophagus or colon. As nisin has already been approved by the FDA and WHO 
for human consumption, along with its non-immunogenic nature and promising in vitro and in 
vivo anti-cancer results, it’s use alongside conventional anti-cancer drugs should be evaluated 
as a step further towards its potential use as a viable therapeutic29.   
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Figure 4.1 MTT % survival results of cell lines KYSE450 and HCT116 untreated and treated 

























Figure 4.2 Colony Formation assay results of cell lines Caco2, HCT116, HT29, KYSE450, 
OE19 and SW620 treated with both 600µg/ml and 800µg/ml of nisin Z for (A) 72hrs and (B) 
96hrs.  
 Clonogenic assays: 72 hrs post treatment























 Clonogenic assays: 96 hrs post treatment
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Figure 4.3 Colonies formations of (A) Caco2, (B) HCT116, (C) KYSE450, (D) SW620, (E) 
OE19 and (F) HT29 cell lines 96hrs post treatment with 600µg/ml and 800µg/ml nisin Z.  
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Figure 4.4 Cytospin results of: (A) HT29, (B) OE19, (C) SW620 and (D) Caco2 cell lines 
96hrs post treatment, and (E) KYSE450 and (F) HCT116 cell lines 72hrs post treatment. 
Figures represent untreated and treated cell with 600µg/ml nisin Z and 800µg/ml nisin Z for 
all cell lines. In the cases of (A), (C), (D) and (F) arrows indicate cytoplasmic blebbing, and in 
the case of (B) and (E) arrows indicate autophagic vacuoles.  
 188 




















PI + Annexin V PI + Annexin V 
PI + Annexin V PI + Annexin V 









Annexin V Annexin V 
































PI + Annexin PI + Annexin 
PI + Annexin PI + Annexin 











































Figure 4.5 Flow cytometry scatter profile of (A) HT29, (B) HCT116, (C) SW620, (D) Caco2, 
(E) OE19 and (F) KYSE450 cells untreated and 96hrs post treatment with 0.05mM 5-FU and 
800µg/ml nisin Z.  
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Figure 4.6 Confocal microscopy results of KYSE450 cells at 72hrs post treatment, represented 
by (A) unlabelled, (B) untreated, (C) treated with 0.05mM 5-FU and (D) treated with 800µg/ml 
nisin Z. Confocal microscopy results of OE19 cells at 72hrs post treatment represented by (E) 
unlabelled, (F) untreated, (G) treated with 0.05mM 5-FU and (H) treated with 800µg/ml nisin 
Z. Ruler indicates 20µm.  
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Beta actin forward 
Beta actin reverse 
5’-TCGTGCGTGACATTAAGGAG-3’ 
5’-CAGGCAGCTCGTAGCTCTTC-3’ 
Table 4.2 Primer sequences used in this study for qRT-PCR. Primers designed using Universal 
Probe Library (Roche Life Science).   
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Figure 4.7 qRT-PCR results for cell lines HCT116 and KYSE450 untreated and treated with 
800µg/ml nisin Z for 96hrs. In the case of HCT116 five sets of primers were evaluated: (A) 
CHOP, (B) Caspase 9, (C) Caspase 8, (D) Caspase 12 and (E) Bcl2. In the case of KYSE450 
three sets of primers were evaluated: (F) CHOP, (G) BNIP3 and (H) Beclin.  
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Figure 4.8 Apoptosis pathways adapted from John C. Reed and Maurizio Pellecchia, 2005, 
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Thesis Summary and Future Work 
  
Lantibiotics are bacterially produced ribosomally synthesised antimicrobial peptides, 
distinguished by the presence of the unusual amino acids lanthionine and methyllanthionine 
which are responsble for the formation of bridges described in these peptides. Nisin and lacticin 
3147 are both well-studied lantibiotics produced by Lactococcus lactis, having antimicrobial 
activity against a wide spectrum of microorganisms in the nanomolar range. Numerous variants 
of nisin have been created through bioengineering techniques to better characterise functional 
properties or exhibit enhanced bioactivity. Reports have also started to emerged analysing the 
possibility of using bacteriocins in a clinical setting. These biomedical applications of 
bacteriocins range from being used as alternatives to antibiotics to being adopted into cancer 
treatment regimes. 
 Chapter I of this thesis reviews the biomedical applications of bacteriocins in relation 
to infection and oncology. Different nisin variants are also discussed along with nisin and 
lacticin’s synergistic effects when used in combination with other animicrobials. Furthermore 
nisin’s innate induction system and its subsequent manipulation is reviewed. 
 Chapter II focuses on the nisin variant nisin-AAA’s self-induction properties when 
amino acids at positions K12 and H31 were independently changed to every other natural 
amino acid. Ultimately, this study highlighted that ten nisin-AAA variants were able to self-
induce without the need for an initial introduction of nisin (in the form of Nisaplin) (original 
nisin K12-AAA-H31, K12V, K12Q, K12W, K12T, K12A, K12C. H31N, H31K and H31R). 
This was apparent from deferred antagonism assays against the known sensitive indicator strain 
L.lactis HP. Further well assays showed the possible connection between induction ability and 
amino acid charge. Negatively charged amino acids D and E at position 12 resulted in the 
 202 
decrease or loss of production and self-induction, whereas sustained self-induction was 
exclusive to the positively charged amino acid K, H, R (and N which is uncharged).  
 Chapter III describes the use of the bacteriocins, nisin Z and lacticin 3147, in 
combination with different antibiotics (penicillin G, vancomycin and methicillin) against 
different indicator strains, C. acnes, E. faecium UCC1, E. feacium UCC2, C. xerosis and 
MRSA ST291. Enhanced antimicrobial activity can be seen when combining lacticin 3147 with 
either penicillin G or vancomycin against all indicator strains. Furthermore, partial synergy 
between nisin Z and methicillin was apparent from FIC assays. This enhanced activity was also 
shown on porcine skin models ex-vivo. Further FIC assays should be conducted to establish 
specific synergistic activity between lacticin 3147 and penicillin G or vancomycin against the 
different indicator strains.  
 Chapter IV investigates the use of the bacteriocin nisin Z as a possible alternative 
therapeutic for colorectal and oesophageal cancers. Nisin Z was shown to induce apoptotic cell 
death in all colorectal cancer cell lines and possible type II (autophagic) cell death in the two 
oesophageal cell lines. In the case of HCT116 cell lines (colorectal) flow cytometry results 
showed that an intrinsic apoptotic pathway was induced by the treatment of nisin. Further 
analysis should be done to determine the exact cell death pathways taken by each cell line used 
in this study when treated with nisin Z. 
 Overall, this thesis makes several contributions to our knowledge of lantibiotics and 
their potential biomedical applications in clinical settings. However, future work should be 
completed to further investigate the effect bacteriocins have on cells of the immune system. 
Cells of the immune system may respond variably to the presence of bacteriocins and the 
upregulation/downregulation of proteins such as cytokines from macrophage cells should be 
investigated. To date no cytotoxic effects of nisin have been reported even when tested at high 
doses of 83.25mg/kg of diet. However, the concentration of nisin required for therapeutic doses 
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well exceeds this and should be further evaluated to ensure its safety for use as a viable 
therapeutic. 
 In relation to using bacteriocins in combination with antibiotics the exact mechanism 
by which nisin Z and lacticin 3147 act synergistically with -lactam antibiotics against -
lactamase producing bacteria still needs to be investigated. It may be that their different modes 
of action weaken the cell to an extent that it cannot recover, but it would also be prudent to 
determine whether -lactamase production is down-regulated. The effect bacteriocins have on 
the gut microbiome should also be considered when determining their use as a therapeutic. 
 Eventhough bacteriocins have shown great success within the food industry and show 
great promise for their biomedical applications, it is clear that further research needs to be done 
on the pharmocokinetic and phamacodynamic properties of administering high therapeutic 















































Figure 5.1 Cytospin results of: (A) HT29, (B) OE19, (C) SW620 and (D) Caco2 cell lines 72 
hrs post treatment, and (E) KYSE450 and (F) HCT116 cell lines 96 hrs post treatment. Figures 
represent untreated and treated cell with 600 µg/ml nisin Z and 800 µg/ml nisin Z for all cell 
lines. In the cases of (A), (C), (D) and (F) arrows indicate cytoplasmic blebbing, and in the 
case of (B) and (E) arrows indicate autophagic vacuoles.  
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Figure 5.2 MTT results % survival results of cell lines HCT116, SW620 and HT29 96 hrs post 
treatment with 400 µg/ml, 600 µg/ml and 800 µg/ml of bactofencin A. 
 207 
Clonogenic assays: 72hrs post treatment




















Figure 5.3 Clonogenic results of cell lines HCT116, Caco2,  HT29, OE19 and SW620 
untreated and treated with 800 µg/ml of bactofencin A for 72 hrs.  
 
 
 
 
 
 
 
 
 
